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ABSTRACT 
Complex samples are commonly problematic in chemistry and pose many 
challenges in both forensic science and natural product extractions. As 
developments in analytical instrumentation affords increases in sensitivity, 
complex samples become more of an issue as previously undetectable levels of 
chemical components can now be identified. There is a demand therefore driving a 
need for improved protocols to deal with the comprehensive data generated from 
this superior technology. This allows the analysts to observe previously 
undetectable analytes, while limiting the impact of the complexity of data analysis. 
As such, investigations into new methodologies are warranted for the isolation and 
identification of drugs in complex samples in both forensic and pharmaceutical 
applications.  
Synthetic cannabinoids are a relatively new class of illicit substance and due 
to the large numbers of emerging compounds, these require attention to aid law 
enforcement agencies. Consequently, in this thesis these compounds have been 
isolated and identified from within complex herbal substrates using a range of 
optimised novel sample preparations and analytical instruments. Likewise, 
methods for mapping the Sun Pharmaceutical Industries Australia opiate 
processing streams were developed, and peaks of interest between stages of the 
process were identified to meet a genuine industrial problem for this multi-national 
company. Changes in the process and the subsequent impact of the molecules 
present was then investigated with the aid of mass spectrometry. This was carried 
out to inform the company of origins of impurities and major differences occurring 
in the extraction line so that better response times to process adjustments can be 
made.        
Two-dimensional high performance liquid chromatography (2D-HPLC) 
was utilised for the separation of opiate extractions from opium poppy (Papaver 
Somniferum). Multidimensional chromatographic separations require the selection 
of two orthogonal columns; this is a labour intensive and time consuming process, 
which in many cases is an entirely trial-and-error approach. This thesis introduces 
a novel blind optimisation method for column selection of a black box of 
constituent components. A data processing pipeline, created in the open source 
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application OpenMS®, was developed to map the components of equal mass within 
the mixture across a library of HPLC columns; 2D-HPLC separation space 
utilisation was compared by measuring the fractional surface coverage, fcoverage. It 
was found that for a test mixture from an opium poppy (Papaver somniferum) 
extract, the combination of diphenyl and C18 stationary phases provided a 
predicted fcoverage of 0.44 and was matched with an actual usage of 0.48. OpenMS®, 
in conjunction with algorithms designed in house, have allowed for a significantly 
quicker selection of two orthogonal columns, which have been optimised for a 2D-
HPLC separation of crude extractions of plant material.  
Principal components analysis (PCA) loading plots were used for the first 
time to elucidate key differences between two-dimensional high performance liquid 
chromatography (2D-HPLC) fingerprint data from samples collected from stages 
along the Papaver somniferum industrial process chemistry workflow. Data 
reduction was completed using a 2D-HPLC peak picking approach as a precursor 
to chemometric analysis. Comparisons of the final stages of product extraction as 
an example, PCA analysis of characteristic 2D-HPLC fingerprints accounted for 
84.9% of variation between the two sample sets measured in triplicate, with 64.7% 
explained by PC1. Loadings plots of PC1 on each sample set identified where the 
significant changes were occurring and normalised bubble plots provided an 
indication of the relative importance of each of these changes. These findings 
highlight 2D-HPLC with appropriate chemometric analysis as a useful tool for the 
exploration of bioactive molecules within biomass. 
Two-dimensional HPLC and PCA was utilised for the first time here to 
develop a map of the morphine and thebaine/oripavine processing streams. In total 
68 samples were analysed, including the main processing line, waste streams and 
crude impurity standards. The major changes between crucial steps in the 
processing were investigated with the biggest changes identified by mass. 
Impurities of interest were also investigated to find if they are a consequence of the 
extraction process or originate in the natural plant product. These findings will 
assist the company in quality control and understanding of the significant impurity 
changes throughout the process.    
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Measures to control the expanding use of synthetic cannabinoids demand 
new analytical methodology to identify and determine compounds within this 
rapidly evolving class. Seven synthetic cannabinoids (AM-2201, UR-144, XLR-
11, A796,260, 5F-AKB-48, PB-22 and 5F-PB-22) were identified to be present in 
eleven herbal products sold in Victoria, Australia, prior to their ban in 2014, using 
a combination of GC-MS, HPLC, ESI-MS, and NMR. An additional cannabinoid 
in a twelfth product was not detected but not identified. In aid of this work nine 
synthetic cannabinoids standards (AM-2201, AB-001, 5F-AB-001, JWH-018, 
JWH-073, 5F-AKB-48, 5F-AB-PINACA, 5F-PB-22 and PB-22) were synthesized 
or purchased. Furthermore, chemiluminescence detection of synthetic cannabinoids 
was investigated using three commonly used reagents: acidic potassium 
permanganate, colloidal manganese(IV), and tris(2,2′‐bipyridine)ruthenium(III). 
Using the permanganate reagent, no chemiluminescence signal was obtained, but 
the manganese(IV) and tris(2,2′‐bipyridine)ruthenium(III) reagents gave 
analytically useful responses with all synthetic cannabinoids under investigation 
except 5F-AKB-48 and 5F-AB-PINACA. Calibration curves for PB-22, 5F-PB-22, 
AM-2201 and 5F-AKB-48, prepared using HPLC with UV absorbance and/or 
chemiluminescence detection, were used to determine the total cannabinoid content 
extracted with methanol (1 mL) from six of the herbal products (10 mg), which 
ranged from 0.082 to 0.77 mg. Limits of detection were determined for all standards 
with both UV absorbance and/or chemiluminescence detection, which ranged from 
1 × 10-7 M to 9 × 10-4 M. A solid phase extraction study was conducted to further 
isolate the synthetic cannabinoid compounds. Six cartridges were trialled and all 
were found to clean up the sample, however a C18 silica cartridge proved superior.    
Solid-state 13C and 19F NMR spectroscopy has been used for the first time 
to detect forensically relevant synthetic cannabinoids on the surface of herbal 
substrates. The 13C spectra showed narrow peak widths suggesting that the 
synthetic additives are deposited in an ordered, potentially crystalline, phase.  
Importantly, the use of solid-state NMR, particularly 19F, offers a relatively fast, 
non-destructive, selective detection protocol for synthetic cannabinoids on complex 
samples and has potential for other applications such as the direct detection of 
pesticides on plants.   
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Complex samples in context 
Complex samples have long been an issue in analytical chemistry and are 
increasingly common due to improvements in instrument sensitivity [1]. Highly 
sensitive methods mean that increasingly low amounts of analyte can be determined 
leading to identification of previously undetermined contaminates. The isolation of 
drugs from complex samples is a priority in both forensic and pharmaceutical 
disciplines, and can be particularly difficult when samples are obtained from natural 
plant sources [2, 3]. Natural product extractions for purposes such as 
pharmaceuticals and food may still contain numerous components, requiring 
multiple steps to purify the target analytes [3]. With the improvement in impurity 
profiling, demands are placed on developing protocols to remove these compounds. 
Also known for sample complexity, testing in the forensic discipline ranges from 
seized crude drugs [4] to biological samples [5] where the target compound is only 
a small portion of the sample. Seized drugs often contain excipients, precursors and 
bulking agents in addition to the main drug which demands the analytical 
techniques be refined to allow efficient analysis of these and other complex 
samples.  
This thesis examines two types of drug sample matrices in detail: opiates 
from poppy straw obtained from Sun Pharmaceuticals and synthetic cannabinoids 
sprayed onto herbal substrates, in conjunction with Victoria Police Forensic 
Services Department. Sun Pharmaceuticals, formerly known as GlaxoSmithKline 
are a pharmaceutical company that employ a complicated multistep extraction 
process to isolate opiates of commercial interest. Synthetic cannabinoids have 
relatively recently been banned in Victoria [6], prompting Victoria police to 
investigate these complex samples in order to develop robust separation and 
identification protocols. 
Opiates 
The opium poppy, thought to have originated in Asia Minor, is one of the 
oldest plants recorded for medical use [7] with evidence suggesting that it could 
have been used as a pain reliever or as a drug of abuse for thousands of years. The 
opium poppy has been referenced in Sumerian clay tablets dating back to 3000BC 
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and in Greek mythology in 850BC [7]. Archaeological evidence has also 
discovered their presence from the Minoan civilisation, dating back to the 14th 
century BC [8].  
Alkaloids can be extracted from many different poppy species including 
Papaver Bracteatum, Papaver Rhoeas and Papaver Setigerum, however, Papaver 
Somniferum is the species cultivated for opium production as it produces the most 
viable amount of opiate products [9]. The opium poppy plant produces natural 
opiate alkaloids, such as morphine and thebaine and in 1806 Sertürner published 
his paper on isolating the first alkaloid (morphine) from the opium poppy [10]. 
After morphine was isolated, other opiates (noscapine, papaverine and thebaine) 
were identified with codeine being isolated in 1833 [10]. Morphine is the highest 
concentrated opiate in the species Papaver somniferum making this an industrially 
significant plant. Metabolically engineered strains of the plant have been developed 
[11] allowing a crop of poppy plants to selectively produce more of specific opiates. 
This has been achieved with selection [12], cross pollination [13], mutation 
breeding [14, 15] and more recently metabolic engineering [16]. Production of 
thebaine and oripavine are among the opiates that have expanded from poppy 
hybrids [14].  
The industrial scale extraction of these alkaloids from the plant is 
commonly done one of two ways. The traditional way involves slicing the capsule 
of the opium poppy and collecting the gum (latex) that oozes out to seal the wound 
and is typically collected 12 - 24 hours later. The latex is then air dried over 
approximately 10 days before the crude opium is stirred every half an hour over a 
1-3 week period in the sun [7], before following a similar method to the following 
technique for isolation of morphine. This method is still used in northern Indian 
regions however it is outdated and inefficient and as such is not used in modern 
processing [7]. The most common extraction method is the use of poppy straw, 
where 83% of the morphine and 91% of thebaine manufactured worldwide utilise 
this approach [17]. The poppy straw contains the upper stalk of the plant including 
the crushed capsule that has been dried and made into straw pellets. These straw 
pellets are subjected to a water and organic solvent extraction process to isolate the 
pharmaceutically beneficial opiate compounds in bulk. This method is utilised by 
Sun Pharmaceutical Industries Australia for their morphine and thebaine crops, 
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with other target opiates being extracted and further processed for purification. The 
four common alkaloids morphine, codeine, oripavine and thebaine are of interest 
in this thesis and are illustrated in Figure 1.1.  
 
a)             b) 
     
c)                d)               
     
Figure 1.1: Structures of the four major opiates a) Morphine, b) Codeine, c) Oripavine 
and d) Thebaine. 
 
Morphine, the main opiate found in the opium poppy (Papaver 
Somniferum), is used as a pain reliever or analgesic for a variety of different types 
of pain and is commonly used in a hospital setting to bring effective relief from 
severe pain [18]. Common side effects of morphine include sedation, euphoria, 
constipation and a lowered blood pressure [7] however the euphoric and addictive 
effect of this drug has also led to the abuse of this medicine and consequently it is 
now a controlled substance along with other opiates [19]. Morphine is commonly 
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harvested as a precursor to the illicit drug heroin (diacetylmorphine), a compound 
that is also legally manufactured in the UK for medical purposes to treat severe pain 
in particular for terminally ill patients, during caesarean sections and other major 
surgeries [20].  
Codeine is a commonly prescribed analgesic and is found in cold and flu 
medication or strong pain relief tablets and is suited to relieve mild to moderately 
strong pain [7]. Oripavine is extracted from an opium poppy that has been 
genetically modified to produce the opiate in a larger quantity and is then used to 
produce other pharmaceutical drugs such as buprenorphine and naltrexone [21]. 
Oripavine is unable to be used as an analgesic despite having an effect comparable 
to morphine, due to its toxicity [22]. The difference in toxicity is noted in safety 
data sheets (SDS), where the LD50 of morphine is 250 mg/kg (rat) compared to 
oripavine with an LD50 of 26.1 mg/kg (intraperitoneal, rat). Likewise, thebaine is 
unable to be utilised due to its high toxicity (LD50 of 114 mg/kg, rat, oral) that 
causes strychnine-like convulsions [23, 24]. Hence it is extracted from the opium 
poppy as a precursor to other pharmaceutically important drugs such as oxycodone, 
oxymorphone, naltrexone, nalbuphine, buprenorphine and etorphine [25].  
Opium poppies are grown on a large scale in countries including Australia, 
India, and Turkey for the pharmaceutical industry. The multinational company Sun 
Pharmaceutical Industries are a medicinal based company responsible for the 
production of morphine and other opiates used in pharmaceuticals. Heritage 
companies to Sun Pharmaceutical Industries Australia (SPIA) have been operating 
in Australia since 1886. In 1964, Glaxo began growing opium poppies in Tasmania 
for the extraction of morphine and other related opioid medications [26]. Since then 
the company has grown significantly, contributing to the global supply of opiate 
pharmaceuticals and in 1995 the company merged to form Glaxo Wellcome and 
more recently GlaxoSmithKline (GSK) (2000-2015). In 2012 GSK invested 
AUD$54 million to research and development [26] with trials in Victoria to 
determine the viability of poppy production on mainland Australia. In 2015 Sun 
Pharmaceuticals purchased the opiate section from GSK and since then has 
continued with the cultivation and processing of important opiate alkaloids. The 
core opiates isolated by Sun Pharmaceuticals are morphine, codeine, oripavine and 
thebaine (Figure 1.1) for use in various medicinal products or as a precursor to 
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many important semi-synthetic opiates. As these bulk opiates are being utilised in 
consumable products it is important to monitor the process for impurities. A 
mapping technique for the extraction process will also help to inform the company 
of what is occurring at critical points in the stream thus facilitating quality control. 
In general mapping techniques allow visualisation of changes by using the data 
collected to identify differences between data sets or in this case, each step of 
manufacturing processes.    
Synthetic cannabinoids 
Synthetic cannabinoids, originally based on naturally occurring 
cannabinoids, were developed as therapeutic agents and possible alternatives to 
THC [27, 28]. However, these failed to diminish the side effects already commonly 
observed from the natural cannabis plant. The first instances of these molecules 
were published in academic journals after development and investigation by 
pharmaceutical industries and researchers in the 1960’s [29, 30].  John W Huffman, 
the inventor of several commonly seized synthetic cannabinoids is also the name 
sake of the compounds starting with JWH, such as JWH-018 [31, 32]. Other 
compounds are either named after their inventor, their base structure or the class in 
which they belong. Examples of this include CP-47,497 which whilst invented by 
Pzifer, is named after its cyclohexylphenol base structure, as are other synthetic 
cannabinoids described with the CP prefix [29].    
Since the early 2000s in Australia [27, 33] a large number of products 
marketed as "legal highs" were readily available in herbal shops and adult stores. 
However, in 2008 these herbal substrates were tested and found to contain 
previously reported synthetic cannabinoid compounds as the active ingredient [29, 
34]. These products consisted of herbal substrates that had been laced with one or 
more synthetic cannabinoid compounds and were then smoked in a similar manner 
to cannabis. These chemicals are commonly white powders or oils that are 
dissolved into acetone or a similar organic solvent and sprayed onto the herbal 
substrates [35, 36]. These substrates are commonly made from the leaves, bark, 
flowers and roots of plants such as damiana (Turnera Diffusa), marshmallow leaf 
(Althaea officinalis) and mullein leaf (Verbascum Thapsus) [37, 38].  
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To date hundreds of different synthetic cannabinoid structures have been 
identified making the detection and identification of these compounds a difficult 
task, and law enforcement agencies are in need of improved protocols [27, 39]. A 
common way to avoid the legislation against the compounds was to make analogues 
or change the structures in such a way that they were no longer illegal. As is the 
case with many of the compounds, an example being UR-144 and XLR-11 where 
the latter has only the addition of a fluorine on the end of the alkyl chain (Figure 
1.2). This is a common analogue along with changes to the aromatic rings or the 
addition of extra carbons on the alkyl chain. This has made the detection of these 
difficult as not all structures have the same properties, prompting a push to find 
alternative/new analytical methods that can selectively detect these compounds.  
 
Figure 1.2: Structures of UR-144 and its fluoro pentyl analogue XLR-11. 
 
To further complicate the chemical fingerprint of these products, fragrances 
and flavourings such as menthol, strawberry, mango and pineapple are added to 
some brands to give a higher appeal to the purchaser. These products, while 
marketed as legal highs, were sold under the radar as potpourri and incense and 
their devastating impact on society is illustrated in Figure 1.3 [40-42]. Most 
products contain labels stating the herbs were ‘not for human consumption’ and 
‘for aromatherapy use only’ with some blends including warnings of the potential 
to get a high, as is illustrated in Figure 1.4 with the brand Cloud 9. 
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Figure 1.3: A snapshot of news headlines relating to the emergence of synthetic 
cannabinoids and the effects caused by these drugs. 
 9 
 
 
Figure 1.4: Warning label on the brand Cloud 9 stating “WARNING: This product is 
intended to be used as incense, for Aromatherapy use only. The deliberate smoking of 
this product may result in you getting high and experiencing hallucinations or 
delusions.” 
 
Synthetic cannabinoids have a similar effect in the body as 
tetrahydrocannabinol (THC) as these compounds interact with the same chemical 
receptors in the brain, Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) [28, 43-45]. 
A series  of emergency department case studies have found users suffer from 
anxiety, tachycardia, tachypnoea, hypertension, hallucinations or psychosis and 
seizures [46]. Hopkins and Gilchrist [47] reported a link between these compounds 
and cannabinoid hyperemesis syndrome (CHS). A common problem found in 
heavy marijuana smokers, CHS is believed to be caused by an over stimulation of 
the CB 1 receptor [47]. As these products gained popularity, more cases of adverse 
side effects were reported with numerous deaths and over doses recorded as 
illustrated in Figure 1.3 by a snapshot of Australian news headlines [48]. Fatal 
intoxication associated with these synthetic drugs has occurred due to organ failure, 
where in particular the kidneys and heart are irreparably damaged [49]. A 
newspaper article in the Geelong Advertiser in December 2013 reported on three 
people in the Geelong Hospital intensive care unit suffering with organ failure after 
using synthetic cannabinoids and numerous others that had reported to emergency 
in the preceding weeks [41].   
As synthetic drugs such as cannabinoids and cathinones are a new craze, 
statistics are yet to reflect the full extent that these products are having on society. 
In 2013 the National Drug Strategy Household Survey (NDSHS) [50] included new 
psychoactive drugs, including synthetic cannabinoids, into the survey for the first 
time. This survey found that 1.3% of Australians aged 14 and over had used 
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synthetic cannabis in the past 12 months, with the most common age group being 
the 14-19 year old range. The Australian data from the Global Drug Survey found 
that in 2014 synthetic cannabis was the 20th most used drug with 4.1% of 
respondents having used the drug in the last 12 months [51]. Even more alarming 
is the findings of the 2016 Global Drug Survey [51] where it was found that for the 
fourth year in a row synthetic cannabinoids have topped the list of drugs ‘leaving 
you most likely to need emergency medical treatment’. The report found that 1 in 
30 people who had used in the last year required emergency medical treatment. 
This is a significant number for a drug that has only been around for 13 years and 
highlights the importance of controlling such dangerous substances.   
In May 2014, a ban was put in place in Victoria, Australia to prevent the 
purchase, sale and possession of 13 classes of synthetic cannabinoids that included 
any analogues of these compounds that fall into one of the specified classes under 
an amendment to the Drugs, Poisons and Controlled Substances Act 1981 [6]. This 
new legislation took into account the previous prohibition of 8 synthetic 
cannabinoids in 2011 [52], and introduced the analogue approach which targeted 
small changes to the molecules that had previously led to the evasion of the initial 
ban. As these compounds are still an issue in Victoria further action is in progress 
with the Drugs, Poisons and Controlled Substances Miscellaneous Amendment Bill 
2017 that introduces a blanket ban of all ‘psychoactive substances’ as was detailed 
in a press release in March 2017 [53], however the bill is still progressing through 
parliament. Due to these recent bans methodology for the detection of these 
compounds needs to be developed. 
 
Separation and Detection methods 
Separation and detection methods for complex samples such as natural plant 
products and synthetic mixtures typically involve techniques including 
chromatography and spectroscopy. Synthetic cannabinoids and opiates have been 
detected with methods such as Mass Spectrometry (MS) [54], Chemiluminescence 
[55] and Nuclear Magnetic Resonance (NMR) spectroscopy [3] post separation 
with analytical systems such as High Performance Liquid Chromatography (HPLC) 
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[17, 37], Gas Chromatography (GC) [56] and Capillary Electrophoresis (CE) [57]. 
A summary of each of these important analytical instruments, including detail about 
HPLC, is outlined below with a targeted summary given in the introduction section 
of relevant results chapters.      
High Performance Liquid Chromatography (HPLC) 
High Performance liquid chromatography (HPLC) is a major tool in 
analytical chemistry and contemporary science for the separation of a vast array of 
compounds [58]. The applications of this already popular technique has steadily 
increased in recent times as a review by Gika et al. in 2015 highlighted, by the 
increase in the number of papers published utilising HPLC (Figure 1.5) [58].  
Reverse phase is the most common HPLC system where a polar mobile phase and 
a non-polar stationary phase are utilised to separate chemical components [59]. This 
chromatography technique separates analytes based on their hydrophobicity due in 
the case of the C18 stationary phase for example to the methylene selectivity of the 
reverse phase column, where polar compounds are eluted first followed by non-
polar compounds [60].   
 
Figure 1.5: An illustration by Gika et al. describing the number of papers published 
utilising high performance liquid chromatography [58] (where liquid chromatography 
and one of the four traces in the graph were searched in the Scopus database in 2014).  
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Reverse-phase HPLC has been used previously for the separation of 
synthetic cannabinoids with the majority of published studies utilising solvent 
gradients of either acetonitrile or methanol in water, with modifiers such as formic 
acid [54]. Other solvent systems employed for the determination of synthetic 
cannabinoids include a gradient of 1:1 methanol: acetonitrile in water [38], and an 
isocratic aqueous sodium acetate buffer [61].  
Reverse phase HPLC is also the method of choice to analyse opiates 
including morphine, thebaine and buprenorphine [62]. Acevska et al. developed 
and validated a reverse phase HPLC method for the resolved separation of six 
targeted opiates [17]. Methods developed for Sun Pharmaceutical Industries 
Australia (formerly GSK) utilise reverse phase HPLC for the analysis of the 
alkaloid processing streams [63].    
  Two-Dimensional High Performance Liquid Chromatography (2D-HPLC) 
In some cases the separation power of a one dimensional system is not 
enough to resolve all components of a sample [64]. In this case two-dimensional 
High Performance Liquid Chromatography (2D-HPLC) has the ability to achieve a 
greater separation power by increasing the peak capacity [65]. Two-dimensional 
High Performance Liquid Chromatography is a technique that utilises two 
orthogonal (different retention mechanism) columns to achieve a greater separation 
potential [66]. This technique can be performed in either offline or online methods. 
Offline 2D HPLC requires the first dimension to be run and the fractions collected 
into vials; subsequently the samples in these vials are then manually reinjected into 
the second dimension [67]. The online method can be done comprehensively or via 
heart cutting, where both utilise a switching valve and sample loops to store 
fractions before transferring these fractions into the second dimension as illustrated 
in Figure 1.6 (a diagram of the system used by Stevenson et al. at Deakin 
University) [68]. In comprehensive 2D-HPLC the whole first dimension is 
transferred into the second dimension whereas in heart cutting only selected peaks 
are forwarded to the second dimension [64]. Online 2D-HPLC is a quicker and 
more efficient method than offline, however it requires the second dimension to 
have a fast flow rate as, in order to avoid peak overlap, the second separation must 
be complete before the first dimension re-fills the sample loop [67].    
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Figure 1.6: Two-position, eight-port switching valve configuration utilised in 2D-HPLC 
separations as described by Stevenson et al. [68] 
 
Other applied separation techniques 
Other separation techniques that have been applied to the substrates 
analysed here include gas chromatography and capillary electrophoresis, however 
they have not been used in this thesis due to the limitations outlined in this section. 
Gas chromatography (GC) is a separation technique commonly used for the 
analysis of a wide variety of volatile compounds. The use of GC is widespread in 
chemistry with applications in forensics [5, 69, 70], pharmaceuticals [71, 72] and 
quality assurance in chemical industries [73], where it is often coupled to mass 
spectrometry (GC-MS). It is essential for GC that the samples are volatile and that 
the compounds to be analysed do not degrade with high temperature. This is an 
issue with some synthetic cannabinoids such as XLR-11 which contain a 
cyclopropyl ring as the ring opens to form a propenyl rearrangement product of the 
original compound when heat is applied [74].   
Capillary electrophoresis (CE) is an analytical technique utilised for 
applications such as pharmaceuticals [57, 75] and forensics [76] where charged 
analytes are separated based on their differing electrophoretic mobility’s. Hindson 
et al. has previously used this technique for the determination of opiate alkaloids in 
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process liquors [77]. However a limitation of this technique is the lack of sensitivity 
or stability often required for forensic applications and as such it is not well 
established in these laboratories [76].   
Chemiluminescence 
Chemiluminescence is the production of light from a chemical reaction 
without the generation of heat [78]. In an analytical chemistry setting the light is 
commonly detected with a photodetector as over a finite range the intensity of the 
light is proportional to the concentration of reactants involved [79]. It is important 
to note that the amount of light produced is not necessarily about how well the 
reagent reacts with an analyte but is due to the production and stability of the 
excited state. This is a system that is easily coupled to HPLC [80, 81] or Flow 
Injection Analysis (FIA) [82, 83] and may be used in conjunction with a UV-
absorbance detector [63, 84].  
There are a range of different chemiluminescence reagents that can be 
utilised for detection and they are typically prioritised based on the chemical 
structure of the target analytes, as each reagent is generally known to elicit light in 
the presence of particular functional groups. [79]. The most common 
chemiluminescence reagents utilised at Deakin University are tris(2,2‐
bipyridine)ruthenium(III) ([Ru(bipy)3]3+), colloidal manganese(IV), acidic 
potassium permanganate and luminol of which the preceding three have been 
utilised in this thesis (Figure 1.7). The use of chemiluminescence is ideally suited 
where selectivity is required. For example the opiates morphine and codeine are 
similar in structure, however they react differently with the aforementioned 
reagents. As described by Francis et al., codeine produces an intense emission with 
[Ru(bipy)3]3+ where a relative intensity of 100 was obtained, but affords minimal 
light with acidic potassium permanganate with a relative intensity of only 2 
observed [55]. Morphine however is the opposite with the relative intensity with 
acidic potassium permanganate observed at 100 as opposed to less than 0.01 with 
the [Ru(bipy)3]3+ reagent [55]. This is proposed to be due to the lack of a phenol in 
codeine that morphine contains, an attribute that elicits light with acidic potassium 
permanganate but quenches [Ru(bipy)3]3+ [79]. However, Lenehan et al. overcame 
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this selectivity by utilising a mix of these two reagents to detect both morphine and 
codeine in the same system [85]. 
a)         b)            c) 
              
Figure 1.7: Structure of a) potassium permanganate, b) [Ru(bipy)3]3+ [55] and c) 
manganese dioxide (Mn(IV)). 
 
A review on chemiluminescence by Adcock et al. highlights the sensitivity 
of the technique with detection limits as low as 1 × 10-11 M reported. Table 1.1 
highlights the use of the following three reagents: [Ru(bipy)3]3+, acidic potassium 
permanganate and colloidal magnesium(IV) for the detection of a range of dugs.    
Table 1.1: Detection limits of a range of opiate based molecules gained 
with three chemiluminescence reagents.  
Analyte Reagent Instrumentation LOD 
Codeine Manganese(IV) FIA 1.0 × 10-8 M [86] 
Thebaine Manganese(IV) FIA 5.0 × 10-9 M [86]
Norfloxacin Manganese(IV) FIA 3.0 × 10-8 M [87] 
Cannabidiol Acidic potassium 
Permanganate 
HPLC 1.0 × 10-6 M [88] 
Oripavine Acidic potassium 
Permanganate 
HPLC 1.0 × 10-9 M [89] 
Morphine Acidic potassium 
Permanganate 
HPLC 7.5 × 10-10 M [89] 
MDMA [Ru(bipy)3]3+ HPLC 4.8 × 10-7 M [90] 
Codeine [Ru(bipy)3]3+ HPLC 5.0 × 10-10 M [63] 
Thebaine [Ru(bipy)3]3+ HPLC 1.0 × 10-9 M [63] 
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[Ru(bipy)3]3+  is particularly useful for the detection of alkaloids, 
biomolecules, pharmaceuticals and controlled drugs containing secondary or 
tertiary amines [90-93]. The [Ru(bipy)3]2+ is first oxidised to [Ru(bipy)3]3+ and then 
reduced by an analyte to produce light and [Ru(bipy)3]2+	ሾ79ሿ. Recently, a highly 
stable form of this reagent was developed by McDermott et al. [91], where the 
complex is prepared as a perchlorate salt which allows the reagent to remain in the 
3+ state for a longer period of time. This reagent has been found to react strongly 
with tertiary amines [78].    
Acidic potassium permanganate was first reportedly used in 1917 to study 
the oxidation of pyrogallol [94] and was also the first reagent used to determine 
morphine in 1986 [95]. The acidic potassium permanganate also known as 
manganese(VII) is proposed to form an excited state manganese(II) species via a 
multi-step reduction with certain analytes, in particular those that contain phenols 
[96]. This reagent has a wide range of analytical applications and has been used 
extensively in pharmaceutical analysis, in particular opiates such as morphine, and 
for illicit drugs, biomolecules, pollutants, antioxidants and pesticides [94, 96].   
The colloidal manganese(IV) reagent was first reported in 2001 and was 
found to produce light with many organic and inorganic compounds when used in 
conjunction with an enhancer such as formaldehyde or ethanol [97]. This reagent 
has a similar mechanism to acidic potassium permanganate where manganese(IV) 
is reduced to manganese(II). This reagent exhibits a broader selectivity than that of 
acidic potassium permanganate and reacts with amino acids, alkaloids, indoles, 
plant-based extracts and analytes of forensic interest [86, 97-101]. This broader 
selectivity is demonstrated with opiate alkaloids where it was found to react with 
both morphine and codeine as opposed to just one as is noted with the previously 
discussed reagents.   
Electrochemiluminescence (ECL) 
Electrochemiluminescence (ECL) is a technique that involves applying a 
potential to an electrode in the presence of a reagent and co-reactant to induce an 
electron-transfer reaction to form light emitting excited states[102]. It was first 
reported for use with Ru(bipy)22+in 1972, where the sample was in acetonitrile with 
the electrolyte tetrabutylammonium tetrafluoroborate [103]. It is commonly used 
 17 
 
in biological and clinical testing [104], food and water assessment [105] and drug 
detection [106]. Microfluidic analytical devices have also used ECL as a detection 
method [104]. This technique is commonly used due to its high sensitivity and 
selectivity that it affords an anlalyst [102, 104].   
Mass Spectrometry (MS) 
Mass spectrometry (MS) is a technique used for the identification of 
compounds by determining the molecular mass and the mass of fragment ions 
[107]. There are three main processes within the mass spectrometer; 1) the sample 
is first ionised and then 2) passed through an electric field, ionic field, magnetic 
sector or drift region where the ions are separated before 3) detection [108]. Mass 
Spectrometry is a technique highly utilised in analytical chemistry for the detection 
and identification of compounds of interest. It is heavily utilised in the 
pharmaceutical industry for the determination of impurities and degradation 
products and is often coupled with GC (gas chromatography), LC (liquid 
chromatography) or CE (capillary electrophoresis) [71]. It is also used extensively 
in forensics for biological samples and the identification of drugs or other 
compounds.  
Mass spectrometry is used in the forensic analysis of synthetic cannabinoids 
and is the main identification technique utilised in conjunction with gas 
chromatography [54]. This technique has been instrumental in identifying new 
compounds where it is coupled to either LC or GC [109-112] and in biological 
testing where it has been used to test for synthetic cannabinoids in substrates such 
as blood [113-115], hair [116, 117] and urine [118, 119].     
Extensive literature is available on the use of mass spectrometry for opiates 
in biological samples [120-122] and in environmental applications to test their 
presence in waste water [123-125]. MS has been instrumental in mapping the 
opium poppy biosynthesis pathways [126] and for identifying opiate alkaloids after 
isolation [127]. Stranska et al. utilised HPLC/MS/MS for the determination of 
alkaloids from empty Papaver somniferum capsules [128]. This technique is most 
commonly used in conjunction with liquid chromatography, where LC/MS is 
commonly used on sites that extract bulk opiates as a quality control measure. 
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Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear Magnetic Resonance (NMR) Spectroscopy is a technique often 
employed for structural determination of a compound. This method has been widely 
employed in both synthetic and analytical chemistry, for structural elucidation or 
confirmation of compounds [108]. NMR is most commonly performed in a solution 
state using a deuterated solvent, however compounds can also be analysed in solid 
state [129]. Solid state NMR is an emerging technique that is often used for the 
analysis of bulk samples and to investigate the surface chemistry of catalysts, 
zeolites and metal organic frameworks [130-132].  
Synthetic cannabinoids have evolved greatly since the discovery of the first 
compounds on marketed "legal high" products. In conjunction with mass 
spectrometry, these emerging compounds are commonly identified with NMR. 
There are a number of papers reporting the use of 13C, 19F and 1H solution state 
NMR for the structural elucidation of these new compounds [110, 133-135]. Fowler 
et al. used 1H NMR and proton correlation spectroscopy to quantitatively identify 
synthetic cannabinoids on herbal blends [136]. Opiate alkaloid compounds have 
also previously been determined using techniques that include NMR [137, 138]. 
Furuya et al. utilised this technique to identify a new alkaloid present in the callous 
tissue of Papaver Somniferum [127].    
 
Data Analysis 
The data obtained from LC/MS and HPLC can often be considerable and 
difficult to handle when dealing with a large number of samples. Due to this, data 
handling software is often employed to minimise the time it takes to interpret the 
information. There are numerous open source software, such as OpenMS® and 
Open chrome, available in addition to the programs supplied by the manufacturers 
of the instrumentation, namely Mass hunter (Agilent), Profiling solutions 
(Shimadzu) and Xcaliber (Thermo Fisher). Mathematica and other programming 
software such as Matlab, allow for better interpretation of complex mass 
spectrometry data and 2D- HPLC. With algorithms designed in house these 
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programs have the potential to determine important data from a large dataset and 
compose heat maps for 2D separations.  
Principal components analysis (PCA) is a common statistical technique to 
determine differences between sample sets and identify the variables. This 
technique was first reported in the literature by Hotelling in 1933 and has since 
been utilised for a vast array of applications.  It has previously been exploited for 
analysis of pharmaceuticals in rats [139], water quality testing [140], food testing 
[141, 142] and wine testing [143, 144].    
   
Project aims 
This project aims to develop improved analytical separation and detection 
capacity for compounds in complex samples. The basis for this work is to 
interrogate complex samples associated with forensic drug detection and 
manufacture of licit drugs in order to enable these industries to best deal with 
priority chemical challenges.   
An efficient method for the selection of orthogonal columns will be 
explored using a combination of multidimensional chromatography, mass 
spectrometry and principal components analysis. The aim is to provide a foundation 
for the development of a separation designed for complex opiate processing stream 
samples. An investigation of all stages of the manufacturing process starting at the 
final product and working back to the starting material, raw poppy straw (Papaver 
somniferum) for the opiate processing streams will be aimed at mapping the 
components in samples from key processing steps. The aim of this is to determine 
if compounds of interest had originated from the raw product or as a consequence 
of the manufacturing process. The work presented here aims to address the mapping 
of the complex opiate manufacturing process so that process owners and industrial 
chemists can respond more efficiently to changes identified in the process stream.   
In the forensic science arena this work aims to exploit novel analytical 
chemistry based on chromatography, chemiluminescence detection and solid state 
nuclear magnetic resonance spectroscopy to selectively determine the presence of 
synthetic cannabinoids on herbal substrates. The project aims to elucidate the 
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chemical composition of synthetic cannabinoids obtained pre-ban in Victoria 
Australia in order to understand the current state of play with synthetic 
cannabinoids in this region. The aim of this component is to understand the 
structure function relationship between a variety of chemiluminescence reagents 
and the synthetic cannabinoids in order to work towards at-scene detection 
chemistry. This aim is to be achieved by comparison of the real world synthetic 
cannabinoids samples and standards purchased or synthesized at Deakin 
University. The fact that synthetic cannabinoids are sprayed onto a herbal substrate 
enables the potential exploitation of solid state nuclear magnetic resonance 
spectroscopy to probe these samples. For the first time solid state NMR will be 
utilised to interrogate synthetic cannabinoids and assess it as a methodology that 
may be useful for policing services. 
Due to the broad nature of the two components of this thesis namely the 
forensic and industrial chemistry more detailed introductory material is given at the 
start of each experimental chapter. This has been performed to inform the reader of 
the key areas of literature relevant to each of these bespoke areas of scientific merit.   
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CHAPTER 2: 
BLIND COLUMN SELECTION PROTOCOL FOR TWO‐
DIMENSIONAL HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY 
  
 22 
 
Chapter Overview 
 This chapter explores the use of an open source program, OpenMS, 
for handling large amounts of mass spectrometry data, to aid the comparison of 
chromatography columns in order to select a pair that will provide the maximum 
use of 2D-HPLC separation space. A greater separation space is represented by a 
large fcoverage indicating that the chromatographic system allows for better resolution 
of compounds in complex samples. The separation was developed using a crude 
morphine poppy extract to represent a real world complex sample matrix. Solvent 
mismatch was investigated in the development of a suitable 2D-HPLC method. 
Once developed, this method was applied to a range of process stream samples 
(morphine, thebaine and oripavine poppy extracts) with the fcoverage for each 
determined in order to fully assess the suitability of the protocol.   
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Introduction 
High performance liquid chromatography (HPLC) is a technique commonly 
used for separating compounds in complex substrates [145] such as biological 
[146], food [147] and environmental [148] samples. The complexity of a sample 
often exceeds the separation potential of traditional HPLC, thus two-dimensional 
HPLC (2D-HPLC) is often performed through separating compounds with the aid 
of more than one chromatography column [149]. The ability to separate complex 
mixtures is greatly increased by using 2D-HPLC as the theoretical peak capacity is 
the product of each individual dimension [149]. However, to achieve the best 
performance, it is vital that the separation chemistries offered by the two stationary 
phases selected are as different (orthogonal) as possible. Consequently, the process 
of achieving this is often onerous, requiring a trial-and-error approach or 
laboriously injecting a series of representative standards [66, 150]. 
Many disciplines have utilised 2D-HPLC including pharmaceutical [151, 
152], forensic [153], environmental [150, 154] and food sciences [68]. As noted 
above, the separation potential of a 2D-HPLC system is determined by the peak 
capacity that is used to describe the chromatographic resolving power [155]. 
Resolution or resolving power of a chromatographic system is defined as the ability 
for peaks to be both Gaussian and base line separated. The peak capacity is 
proportional to the fractional coverage defined by Watson et al. [156] according to 
Equation 1:   
 
௖݂௢௩௘௥௔௚௘ ൌ ∑ୠ୧୬ୱ௉మ    (Equation 1) 
 
where fcoverage is the proportional surface coverage that ranges from 0 to 1, ∑bins is 
the number of bins (the segmented components of the analogue data signal) that 
contain peaks, and P2 is the total number of available bins. The proportional surface 
coverage is directly related to the two-dimensional peak capacity, Equation 2, 
which illustrates that the full advantage of a 2D-HPLC separation will only be 
realised by maximising the fcoverage term [155]: 
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 ݊௖,ଶ஽ ൌ ௡೎,భൈ	௡೎,మൈ	௙೎೚ೡ೐ೝೌ೒೐ழఉவ     (Equation 2) 
 
where, nc,2D is the practical 2D-HPLC peak capacity, nc,i is the peak capacity in 
separation dimension i, fcoverage is the proportional amount of separation space 
utilisation, and ൏ ߚ ൐ is the under-sampling correction factor, which is directly 
proportional to the modulation frequency per peak from the first dimension to the 
second, as described by Li and co-workers [157]. This is achieved through a given 
number of bins used to divide the separation space, Σbins, that is equal to the 
number of peaks; the area of all normalised bins containing peaks is then totalled 
giving P2 [158]. Using this method, the fcoverage is calculated as a number between 
0 and 1 with the value of 1 indicating full use of the separation space. Gilar et al. 
[158] illustrated the use of separation space as shown in Figure 2.1, where it is 
important to achieve a separation that is not in a diagonal line and utilises the space 
available in the square otherwise low orthogonality is achieved.  
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Figure 2.1: Representation of separation space utility by Gilar et al. [158] where (A) is a 
non-orthogonal separation representing 0% orthogonality, (B) is a hypothetical, full use 
of separation space and (C) is an ideal system representing 100% orthogonality.    
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The separation space is maximised using orthogonal columns; however, 
finding two columns that fit this requirement can be a lengthy and difficult task 
[66]. Previously, analysing the relative retention profile of each HPLC column 
against each other was the only way to identify the best separation. Murahashi and 
co-workers [150] selected columns based on differing elution orders by injecting 
five standards into eight columns. This was further explored by Bassanese et al. 
[66], but it was found that matching peaks by their area with HPLC proved 
problematic between different columns when using the sample itself as the 
optimisation matrix. Moreover, it was not practical when performing single 
injections of a comprehensive series of representative standards. Other methods 
include selecting column stationary phases on the knowledge that they are unlikely 
to produce similar separations based on the interactions of the compounds being 
analysed [68]. These techniques were found to be incredibly time consuming and 
difficult to achieve when the components of the sample being analysed are 
unknown [66]. 
For an unknown mixture, one way to match peaks from different separations 
is to compare their molecular weight. Mass spectrometry is a technique used for the 
identification of compounds by determining the molecular mass and is particularly 
important when a greater understanding of the analytes is required [159]. Mass 
spectrometry is superior to UV-absorbance detection when analysing complex 
sample extractions as it provides an information rich snapshot of the elution such 
as a mass associated with each compound in the mixture. This technique also allows 
a fingerprint of the sample where the fragmentation pattern can discriminate 
between compounds of the same mass [160] thus providing greater information on 
the components in complex mixtures than UV-absorbance detection affords. Mass 
spectrometry is often coupled with LC (liquid chromatography), GC (gas 
chromatography) or CE (capillary electrophoresis) to enhance knowledge of the 
concomitant species of a sample [161]. This is particularly important for unknown 
samples where as much information as possible is essential for further analysis. 
This technique has been utilised in this selectivity study to provide as much 
information about the peaks as possible, which can then be used to compare the 
columns via the masses of the peaks in the sample.   
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One of the greatest challenges in dealing with mass spectrometry is 
handling the enormous amount of data generated. This problem is further 
exaggerated by the creation of two-dimensional separations. Consequently, 
OpenMS® (version 1.11.1), a program used to manage and analyse data obtained 
by mass spectrometry, will be explored to interrogate the complex set of 
chromatographic information. In comparison to other programs that are available 
for mass spectrometry data analysis, OpenMS® offers a more flexible platform as 
the user is able to combine components of the software to suit their individual 
requirements [162]. Using this program, filters can be applied to the mass spectra 
to extract important information, such as particular peaks of interest. There are a 
large number of pipelines that can be followed to obtain the desired outcome for 
the analysis, including a simple pipeline that eliminates noise from the spectra or 
increasingly more complex pipelines that incorporate a number of filters and peak 
picking tools. Visualisation at stages through the pipeline with the TOPPView 
feature is also an important element, allowing the user to open a single spectrum or 
a peak map in either two or three dimensions [163]. 
A major difficulty in the optimisation of 2D-HPLC operating conditions is 
the selection of columns with divergent retention mechanisms [66]. The aim of this 
work is to introduce a new approach to remove the guesswork in column selection; 
the methods developed in this study are not limited to alkaloids but represent a 
reliable column selection protocol that can be applied to any complex sample where 
the constituent components are unknown. This chapter presents an approach to 
optimise column selection in 2D-HPLC with a wide range of applications, and is 
illustrated here by the separation of crude opiate extracts. Sixteen columns were 
used to separate the components within the concentrate of (morphine) poppy straw 
(CPS) using LC/MS. OpenMS® was used to evaluate data from each column and 
determine which two columns together will provide the best use of separation 
space. The selected columns were then used to develop an appropriate 2D-HPLC 
method that was applied to additional opiate samples. This method took into 
account solvent mismatch from the first to second dimension and optimised both to 
allow for the requirement of a fast flow rate in the latter.       
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Experimental 
Chemicals and samples 
Water was obtained from a Milli-Q filtration system (Merck Millipore, 
Victoria, Australia). HPLC grade acetonitrile (ACN) was purchased from Ajax 
Finechem Pty. Ltd. (Taren Point, NSW, Australia). Trifluoroacetic acid was 
purchased from Sigma-Aldrich and formic acid was purchased from Hopkin and 
Williams (Essex, UK). Crude morphine and other opiate samples were supplied by 
Sun Pharmaceutical Industries Australia Pty (Port Fairy, Victoria, Australia) that 
were extracted from Papaver somniferum following proprietary protocols. All solid 
samples were prepared at a concentration of 10 mg mL-1 in water prior to LC/MS 
analysis and liquid samples were diluted by a factor of 10 with 10% acetic acid 
(VWR International, Fontenay-sous-Bois, France).  
Standards were made up into a 10 mL acetonitrile stock with 10 mg each of 
thiourea, caffeine, phenol, anthracene and 10 µL of dimethyl phthalate and n-propyl 
benzene (purchased from Sigma-Aldrich Pty Ltd, Castle Hill, NSW, Australia). 
The standard stock was then added (50 µL) to 6 different compositions of 
acetonitrile (50 µL, 200 µL, 400 µL, 500 µL and 600 µL) making up 1 mL with 
water. Viscosity was adjusted to address solvent mismatch by adding an appropriate 
amount of either isopropyl alcohol or ethanol (Chem-Supply Pty Ltd, Gillman SA, 
Australia) according to viscosity calculations (Table 2.3).  
Liquid Chromatography Mass Spectrometry (LC/MS) 
Mass spectrometry analysis was performed with an Agilent Technologies 
6210 LC/MSD TOF system (Agilent Technologies, Mulgrave, Victoria, Australia). 
It was equipped with an Agilent technologies 1200 series solvent degasser, binary 
pump and an Agilent technologies 1100 series autosampler (ALS). Positive ion 
polarity was used in conjunction with nitrogen drying gas (5 L min-1) and nitrogen 
nebuliser gas (30 psi). The morphine sample was injected (5 µL) into a linear 
gradient over 40 minutes with an initial mobile phase of 5% ACN (95% water) that 
increased to 100% ACN. All analyses were run at a flow rate of 0.5 mL min-1. 
Chromatographic data were obtained and processed with Agilent ChemStation 
software. The sixteen columns that comprised the stationary phase library for this 
study are listed in Table 2.1. 
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Table 2.1. Details of the HPLC columns utilised. 
 BRAND TYPE SIZE DIMENSIONS PART NUMBER 
Column 1 Agilent Poroshell 120 EC-C8 2.7 µm 4.6 ×100 mm 695975-906 
Column 2 Agilent Poroshell 120 EC-CN 2.7 µm 4.6 × 100 mm 695975-905 
Column 3 Phenomenex Kinetex PFP 100 Å 2.6 µm 4.6 × 100 mm 00D-4477-EO 
Column 4 Phenomenex Kinetex Phenyl-Hexyl 100 Å 2.6 µm 4.6 × 100 mm 00D-4495-EO 
Column 5 Phenomenex Synergi Fusion - RP 80 Å 4 µm 4.6 × 150 mm 00F-4424-EO 
Column 6 Phenomenex Synergi Hydro - RP 80 Å 4 µm 4.6 × 150 mm 00F-4375-EO 
Column 7 Phenomenex Luna C5 100 Å 5 µm 4.6 × 50 mm 00B-4043-EO 
Column 8 Phenomenex Luna HILIC 200 Å 5 µm 4.6 × 150 mm 00F-4450-EO 
Column 9 Cosmosil Cosmosil πNAP 2.5 µm 4.6 × 100 mm 08084-51 
Column 10 Cosmosil Cosmosil 5PBB-R 5 µm 4.6 × 150 mm 05697-21 
Column 11 Cosmosil Cosmosil 5NPE 5 µm 4.6 × 150 mm 37904-01 
Column 12 Agilent Poroshell 120 EC-C18 2.7 µm 4.6 × 100 mm 695975-902 
Column 13 Agilent Poroshell HPH-C18 2.7 µm 4.6 × 100 mm 695975-702 
Column 14 Agilent Poroshell 120,SB-C18 2.7 µm 4.6 × 100 mm 685975-902 
Column 15 Agilent Poroshell 120 Bonus RP 2.7 µm 4.6 × 100 mm 695968-901 
Column 16 Agilent Pursuit XRs 3 Diphenyl 3 µm 4.6 × 100 mm A6021100X046 
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Two-Dimensional High Performance Liquid Chromatography 
An Agilent Technologies (Mulgrave, Vic., Australia) 1290 2D 
chromatograph was used for all separations, including: an auto sampler; solvent 
degasser; capillary pump; binary pump; quaternary pump; column thermostat; 2 
position 8 port switching valve; and two diode array detectors (one in each 
dimension, both of which monitored absorbance at 210 nm and 254 nm). The 2D-
HPLC separations were performed using 100 µL injections and a controlled 
temperature of 25°C. All mobile phases contained 0.1 % formic acid. The first 
dimension was completed at a flow rate of 0.1 mL min-1 with an initial mobile phase 
of 15% ACN (85% water) that increased to 40% ACN over 40 minutes, increasing 
to 60% ACN over a further 20 minutes and was then isocratic (60% ACN) for a 
further 30 minutes. A counter gradient was used in the first dimension, after the 
column, with an initial mobile phase of 9% ACN (91% water) to 4% ACN over the 
first 40 minutes, decreasing to 0% ACN over the next 20 minutes and was then 
isocratic at 100% water for a further 30 minutes at a flow rate of 0.5 mL min-1. The 
second dimension was completed at 2 mL min-1 with an initial mobile phase of 10% 
ACN (90% water) that increased to 15% ACN over 2 minutes, increasing to 60% 
ACN over a further minute. Thus, the comprehensive two-dimensional separation 
had an overall completion time of 90 minutes. Two-dimensional HPLC was 
completed on-line with a modulation time of 4 minutes, whereby a fraction volume 
of 75 µL was transferred to the second dimension via a sample loop (500 µL) and 
switching valve that was controlled with the HPLC control software. It should be 
noted that ACN was used throughout as due to solvent mismatch it is of significance 
to two dimensional chromatography 
Data analysis 
The chromatographic data obtained from the LC/MS was analysed with 
OpenMS® 1.11.1 [162, 163]. The OpenMS® pipeline included a file converter, file 
filter, resampler, noise filter (Savitzky Golay), peak picker wavelet, feature finder 
(metabo) (metabolite features), collect, feature linker (unlabelled QT) and a text 
exporter. Output files were present at the feature finder, feature linker and the text 
exporter. All parameters within these tools were default except in the file filter 
where m/z values were specified to be within the range of 50-700 and intensity 
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values were set to a range 1,000-30,000,000 counts. The output files from 
OpenMS® consisted of a list of retention times for features that were common 
amongst the investigated HPLC columns. This data was processed with Wolfram 
Mathematica 10 (distributed by SHI UK, Milton Keynes, England) to match these 
retention times and predict the relative retention behaviour using algorithms written 
in-house to inform the analyst of possible orthogonal columns. Two-dimensional 
contour plots were prepared with Wolfram Mathematica 10. 
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Results and discussion 
Identifying the columns that provide the greatest separation space utilisation 
for 2D-HPLC can be a labour intensive process, particularly when comparing 
column combinations individually [150]. Previous researchers have attempted to 
shorten the process of identifying orthogonal columns however issues such as 
differing peak elution times on the variety of columns tested and unknown sample 
matrices [66] has prompted the use of LC/MS to manage the peaks using molecular 
masses which overcomes these issues and allows for an accurate comparison of the 
columns. When analysing a complex sample matrix, where the components are 
completely unknown, using standards to aid in column selection is not possible [66] 
as they may not accurately represent the unknown compounds from a structural 
perspective. 
OpenMS® was used here to identify the columns that achieved a high 
degree of fcoverage in a 2D-HPLC separation of an opium poppy extract. Although 
this was not its intended purpose, it allowed a large variety of columns (256 
combinations) to be compared in a significantly reduced time relative to the 
traditional trial-and-error process. Additional benefits were obtained with a 
reduction in method development costs, volume of solvent needed and amount of 
sample required. Method development expenditure is a significant factor in 
industry, where a more efficient outcome reduces the time and wage of employees 
which is a major cost to the company.  
OpenMS® was able to help process the data from each column based on 
the masses obtained from the actual samples. The information pipeline that was 
used by OpenMS® in this work is illustrated in Figure 2.2, which outlines the data 
processing pipeline utilised to identify the most orthogonal columns.  
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Figure: 2.2: The final OpenMS® pipeline applied to map peaks of common mass 
between HPLC columns. 
 
The initial part of the pipeline (highlighted in red) was used to analyse 
samples for each of the different columns individually; this included a file 
converter, resampler, noise filter, peak picker, and feature finder. In order for 
OpenMS® to be able to read the mass spectrometry data files, they were converted 
from the file format .mzdata to .mzml. The customised pipeline then employed a 
file filter where parameters such as intensity, retention times and m/z values were 
optimised to focus on the areas of interest [162]. These parameters were optimised 
through the TOPPView feature of OpenMS® as shown in Figure 2.3. For this 
pipeline, a set of rules were developed to selectively extract the mass values (50 to 
700) from each of the input files. The LC/MS map was then transformed into a re-
sampled map before a noise filter was employed. The noise filter ‘Savitzky Golay’ 
was utilised for this data to smooth the baseline and eliminate peaks caused by noise 
[163]. The peaks in each of the samples were then acquired from the mass spectra 
using the ‘peak picker wavelet’, and all features found using the ‘feature finder 
metabo’ [163]. In the second stage of the pipeline (shown in green) each of the 
individual files were collected together. The ‘feature linker unlabelled QT’ then 
grouped the corresponding features from multiple maps to produce an output file 
[163]. From this pipeline, results were then statistically processed using 
Mathematica and algorithms designed in house. 
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SGolay 
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Figure 2.3: Thebaine sample a) before optimised parameters, b) optimised parameters 
(m/z values: 50-700 and intensity 1,000 – 1,000,000) 
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Table 2.2 lists the expected fcoverage for each column combination after using 
OpenMS® to extract the retention times of features from LC/MS chromatographic 
data and Mathematica to predict the fractional surface coverage when combined in 
a hypothetical 2D-HPLC analysis. From the sixteen columns tested with CPS 
morphine, the two columns that displayed the greatest predicted fcoverage were 
identified as the Agilent Pursuit XRs 3 Diphenyl and the Agilent Poroshell 120 EC-
C18, with an expected fcoverage of 0.48 (Figure 2.4A). The retention mechanisms of 
these stationary phases are different and should therefore operate on distinct aspects 
of the analytes’ chemical structure. For example, diphenyl columns comprise of 
two phenyl groups that are connected via a silica group and are suited to separate 
aromatic compounds due to their strong dipole-dipole hydrogen bonding and π-π 
interactions [164]. Surfaces that utilise these π-π interactions have been previously 
used for the separation of opiate compounds and natural product extractions at large 
[165]. To contrast the diphenyl separation mechanism, the C18 column separates 
on the basis of analyte size and hydrophobicity via a chain of 18 carbons [166]. The 
C18 surface is the workhorse of modern chromatography and has myriad 
applications leading to its almost universal use in modern HPLC separations [167]. 
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Table 2.2. Predicted fcoverage of each column combination. Refer to Table 2.1 for column identification. 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1  0.44 0.12 0.32 0.24 0.16 0.16 0.20 0.20 0.28 0.24 0.12 0.20 016 0.32 0.24 
2 0.44  0.16 0.20 0.24 0.20 0.28 0.28 0.16 0.32 0.24 0.28 0.16 0.24 0.40 0.24 
3 0.12 0.16  0.12 0.20 0.20 0.40 0.36 0.16 0.36 0.40 0.32 0.16 0.36 0.16 0.20 
4 0.32 0.20 0.12  0.24 0.12 0.16 0.20 0.16 0.20 0.36 0.12 0.36 0.16 0.40 0.16 
5 0.24 0.24 0.20 0.24  0.16 0.16 0.24 0.28 0.12 0.16 0.20 0.24 0.20 0.36 0.24 
6 0.16 0.20 0.20 0.12 0.16  0.12 0.24 0.20 0.20 0.40 0.16 0.20 0.12 0.24 0.20 
7 0.16 0.28 0.40 0.16 0.16 0.12  0.16 0.20 0.28 0.20 0.16 0.16 0.16 0.16 0.24 
8 0.20 0.28 0.36 0.20 0.24 0.24 0.16  0.24 0.16 0.32 0.28 0.20 0.24 0.36 0.24 
9 0.20 0.16 0.16 0.16 0.28 0.20 0.20 0.24  0.40 0.28 0.16 0.16 0.20 0.20 0.28 
10 0.28 0.32 0.36 0.20 0.12 0.20 0.28 0.16 0.40  0.36 0.40 0.24 0.24 0.28 0.32 
11 0.24 0.24 0.40 0.36 0.16 0.40 0.20 0.32 0.28 0.36  0.20 0.24 0.24 0.28 0.32 
12 0.12 0.28 0.32 0.12 0.20 0.16 0.16 0.28 0.16 0.40 0.20  0.20 0.16 0.16 0.48 
13 0.20 0.16 0.16 0.36 0.24 0.20 0.16 0.20 0.16 0.24 0.24 0.20  0.20 0.36 0.20 
14 0.16 0.24 0.36 0.16 0.20 0.12 0.16 0.24 0.20 0.24 0.24 0.16 0.20  0.16 0.24 
15 0.32 0.40 0.16 0.40 0.36 0.24 0.16 0.36 0.20 0.28 0.28 0.16 0.36 0.16  0.20 
16 0.24 0.24 0.20 0.16 0.24 0.20 0.24 0.24 0.28 0.32 0.32 0.48 0.20 0.24 0.20  
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The two plots in Figure 2.4 demonstrate the bins used for the predicted 
separation. A value of orthogonality can tell how much of the fcoverage the separation 
is utilising, however it is not indicative of where the space is being used. If a 
predicted plot is too correlated (diagonal trend) it indicates that the two stationary 
phases are operating in a very similar manner which in turn leads to an inefficient 
separation of compounds in both dimensions [158]. This could lead to a separation 
only in the first dimension and thus no benefit is achieved by using a second 
column. This is illustrated in Figure 2.4A and B, with the latter demonstrating a 
correlated separation where the bins are all located along the diagonal and uses 
minimal bins with an fcoverage of only 0.20. Figure 2.4A however has a much larger 
fcoverage of 0.48 and is less correlated, thus should have a better stationary phase 
separation.  The difference here shows the significance behind this method as it 
allows an elimination of two columns that are not orthogonal. 
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(A) 
 
(B)  
 
Figure 2.4. Scaled retention times of peaks predicted by OpenMS® and the associated 
occupied bins that have been filled in the fcoverage calculation for (A) Agilent Pursuit XRs 3 
Diphenyl and Agilent Poroshell EC-C18 and (B) Cosmosil πNAP and Phenomenex 
Synergi Fusion.  
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Comprehensive online 2D-HPLC requires that the second dimension be 
significantly shorter than the first, requiring optimisation of the columns selected 
to obtain the fastest possible separation [149]. Due to the requirement of a quick 
second dimension, the methods that were utilised to produce the LC/MS maps were 
unsuitable to use for the 2D-HPLC analysis. Another consideration is solvent 
mismatch from the first to the second dimension which can potentially cause 
viscous fingering and a solvent front that is visible on chromatograms as band 
broadening, where the peaks are shorter and wider [168] and can increase retention 
times [169]. This is illustrated in Figure 2.5 where a chromatogram produced by 
Mayfield et al. [170] highlights the effects of viscous fingering.  
 
Figure 2.5: Representative chromatogram by Mayfield et al. [170] highlighting the 
effects of viscous fingering on a HPLC separation.  
 
A counter gradient is another method that can address differing 
compositions thus eliminating the solvent front formed by mismatched starting 
compositions and as such it was investigated here during method development. A 
counter gradient utilises a third pump and enters the system after the first dimension 
column but before transferring to the second dimension ensuring that the fraction 
matches the starting mobile phase composition in the second dimension. This 
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method developed by Stevenson et al. [171] was shown to significantly improve 
the peak shape of a separation and as such was trialled here in both online and 
offline with a determination that a counter gradient significantly improves the 
separation by eliminating the large solvent front, which can be an issue in particular 
when viscous fingering is formed [172]. 
 
 
Figure 2.6: Illustration of viscous fingering as determined by Catchepoole et al. in the 
paper “Visualising the onset of viscous fingering in chromatography columns” [168].  
 
    Viscous fingering is a mismatch in solvent viscosity that results in fingers 
of the heavy solvent leaching into the less viscous solvent instead of having a linear 
approach. This is illustrated in Figure 2.6, where Catchpoole et al. added dye to the 
more viscous solution and injected into a clear column [168]. In an attempt to solve 
this problem in an alternate way to a counter gradient, isopropanol was added to a 
sample of six standards in a series of differing injection compositions. This was 
based on the paper by Stevenson et al. [171] where this technique was used to 
predict a counter gradient. Both ethanol and isopropanol were tested to match the 
viscosity of the solvent being injected into the second dimension. These two 
solvents were added in the amount calculated using kinetic viscosity (Table 2.3), 
where kinetic viscosity is: 
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ܭ݅݊݁ݐ݅ܿ	ݒ݅ݏܿ݋ݏ݅ݐݕ ൌ ୢ୷୬ୟ୫୧ୡ	୴୧ୱୡ୭ୱ୧୲୷ୢୣ୬ୱ୧୲୷               Equation 3   
 
The kinetic viscosity of acetonitrile was calculated to be 0.439 mm2 s-1, 
water as 0.8926 mm2 s-1, isopropanol as 2.494 mm2 s-1 and ethanol as 1.232 mm2 s-
1. These values were used to calculate the required amount of isopropanol or ethanol 
to match the viscosity of the starting composition. 
Table 2.3. The viscosity calculations for isopropanol and ethanol.  
Acetonitrile 
(%v/v) 
Water (%v/v) Isopropanol 
(mL) 
Ethanol (mL) 
0.05 0.95 0 0 
0.20 0.80 0.1275 0.3423 
0.30 0.70 0.2125 0.5704 
0.40 0.60 0.2975 0.7986 
0.50 0.50 0.3825 1.0268 
0.60 0.40 0.4675 1.2549 
 
A starting percentage of 5% acetonitrile was utilised as it is a very common 
initial mobile phase composition and the values were then increased at regular 
intervals until 60% acetonitrile. It was observed that the peak shape of the standards 
was not significantly improved by the addition of a viscosity altering additive as 
shown in Figure 2.7.  
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Figure 2.7: Separation of standards, a) sample just contains standards, b) standards 
containing isopropyl alcohol and c) standards containing ethanol at 0.4 %  Acetonitrile, 
0.6 % water and 0.2975 mL-1 isopropanol or 0.7986 mL-1 ethanol 
 
This led to the use of a counter gradient instead as this eliminated the solvent 
front issue from the first to second dimension. The counter gradient was calculated 
based on the Stevenson et al. [171] paper and the need for this is illustrated in Figure 
2.8B and 2.9B where a solvent front is visible in the 2D-HPLC bins and contour 
plots.  
To reduce back-pressure concerns when operating at an elevated flowrate 
in the second dimension, the 100 mm Poroshell C18 column tested with mass 
spectrometry was substituted with a 50 mm Poroshell C18. With this column 
length, all components of the sample were eluted within 3 minutes. Despite the 
adjustments to the second dimension, the fcoverage achieved when these two columns 
were utilised was 0.43 (Figure 2.8A and 2.9A), which is only slightly less than 
predicted (0.48).  
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(A) 
 
(B) 
 
Figure 2.8. Scaled retention times of peaks identified from peak picking algorithm and 
occupied bins of the 2D-HPLC separation of opiate alkaloids for (A) Agilent Pursuit XRs 
3 Diphenyl and Agilent Poroshell EC-C18 and (B) Cosmosil πNAP and Phenomenex 
Synergi Fusion. 
 
Diphenyl(Normalised retention time) 
πNAP (normalised retention time) 
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A column combination with a low fcoverage was also investigated to validate 
LC/MS mapping across columns and determine the reliability of this method. The 
Cosmosil πNAP and Phenomenex Synergi Fusion-RP columns were expected to 
operate via similar retention mechanisms, with the πNAP having preferential 
retention to aromatic compounds through π-π interactions and the Fusion-RP being 
a polar embedded C18; however, after mapping the masses between these columns, 
a fcoverage of 0.20 was expected (Figure 2.8B). After performing the 2D-HPLC 
analysis of the opiate extraction with the πNAP column in the first dimension, the 
analysis was determined to have an fcoverage of 0.34 (Figure 2.9B). The 2D-HPLC 
plots for the combination of diphenyl × EC-C18 and πNAP × Synergi Fusion are 
represented in Figure 2.9A and 2.9B, respectively. In the OpenMS® prediction the 
components were correlated, which was also observed in the real sample; however, 
the actual analysis did give a significantly higher fcoverage than predicted. This was 
due to the solvent mismatch from the first dimension to the second dimension 
artificially decreasing the retention time of some of the peaks [171]. 
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(A) 
 
(B) 
 
Figure 2.9. (A) 2D-HPLC plot using an Agilent pursuit XRs 3 Diphenyl in the first 
dimension and a Phenomenex Poroshell 120 EC-C18 in the second dimension. (B) 
Illustration of a 2D-HPLC separation with a small fcoverage: the first dimension (πNAP) 
was completed at a flow rate of 0.05 mL min-1 with an initial mobile phase of 15% 
aqueous ACN that increased to 55% aqueous ACN over 200 minutes and was isocratic 
(55% aqueous ACN) for a further 10 minutes. The second dimension (Synergi fusion) was 
completed at 2 mL min-1 with an initial mobile phase of 20% aqueous ACN that increased 
to 60% aqueous ACN over 3 minutes. Two-dimensional HPLC was completed on-line 
with a modulation time of 5 minutes and completion time of 210 minutes. 
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The separations were optimised with a sample from the later stages (data 
above) of the extraction process in order to use a less complex opiate alkaloid 
sample, so as to not overload the computing processors (4 Gig 8 core which is 
typical of a standard computer as of 2017). As the previous approach showed 
successful multidimensional separation of the opiates, the universal capabilities of 
the methodology were tested with other more complex opiate samples (data below) 
from the Sun Pharmaceutical extraction process. The opiate processing stream and 
impurity standards consisted of 68 samples that have all been analysed with this 
2D-HPLC method. The following two-dimensional plots (Figure 2.10 and 2.11) 
confirm that the protocol developed can be applied to a variety of opiate samples 
and afford a separation of the components in a complex sample. An identical 
method was used when scaling up the complexity of the separation and the degree 
of space utilisation was maintained.  
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a) 
 
b) 
 
Figure 2.10: fcoverage plots for the samples (a) G1527-030G (0.47) and (b) G1527-027C 
(0.47). 
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   a) 
b)  
 
Figure 2.11. Two example 2D-HPLC chromatograms (G1527-030O and G1527-027C) 
representing complex samples from an opiate alkaloid extraction process line. (Please 
note Purple represents minima in this example set at zero and Red maxima) 
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 Table 2.4: fcoverage calculated from each stage of the processing stream 
Sample Average fcoverage Sample Average fcoverage 
G1527-027A 0.39 G1527-028A 0.38 
G1527-027B 0.42 G1527-028B 0.33 
G1527-027C 0.45 G1527-028C 0.32 
G1527-027D 0.39 G1527-028D 0.34 
G1527-027E 0.37 G1527-028E 0.34 
G1527-027F 0.36 G1527-028F 0.40 
G1527-027G 0.37 G1527-028G 0.38 
G1527-027H 0.36 G1527-028H 0.44 
G1527-027I 0.37 G1527-028I 0.40 
G1527-027J 0.43 G1527-028J 0.38 
G1527-027K 0.37 G1527-028K 0.41 
G1527-027L 0.35 G1527-028L 0.43 
G1527-027M 0.36 G1527-030A 0.37 
G1527-027N 0.40 G1527-030B 0.40 
G1527-027O 0.37 G1527-030C 0.38 
G1527-027P 0.39 G1527-030D 0.39 
G1527-027Q 0.39 G1527-030E 0.36 
G1527-027R 0.37 G1527-030F 0.36 
G1527-032A 0.41 G1527-030G 0.36 
G1527-032B 0.29 G1527-030H 0.29 
G1527-032C 0.32 G1527-030I 0.39 
G1527-032D 0.24 G1527-030J 0.32 
G1527-034A 0.29 G1527-030K 0.33 
G1527-034B 0.31 G1527-030L 0.30 
G1527-034C 0.41 G1527-030M 0.36 
G1527-034D 0.36 G1527-030N 0.42 
G1527-034E 0.31 G1527-030O 0.46 
G1527-034F 0.41 G1558-131A 0.41 
G1527-034G 0.39 G1558-131B 0.31 
G1527-034H 0.34 G1558-131C 0.40 
G1527-034I 0.32 G1558-131D 0.41 
G1527-034J 0.32 G1558-131E 0.37 
G1527-034K 0.39 G1558-131F 0.37 
G1527-034L 0.39 G1527-034M 0.36 
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Some of these samples contain a large number of compounds whilst others 
are not as complex which is noticeable from the fcoverage’s determined from each 
stage of the processing stream as shown in Table 2.4. Using previously described 
peak picking algorithms and the bins method, the measured average fcoverage of the 
complicated extracts vary between 0.24 and 0.46 depending on the complexity of 
the sample. The lowest average fcoverage achieved was 0.24, however this sample is 
an impurity standard papaveraldine, where there are only a few other components 
present beside the major peak. The largest average fcoverage achieved was 0.46 for 
the sample G1527-030O which consists of the mother liquor after the target 
compound oripavine has been precipitated out of the processing stream. The 
complex sample G1527-027C is from the start of the morphine processing stream 
and had the next greatest average fcoverage at 0.45. The fcoverage plots for G157-030O 
and G1527-027C are illustrated in Figure 2.10a and 2.10b respectively, where it is 
evident that a large amount of the available separation space is utilised and the 
peaks are not focused along the diagonal line. The 2D-HPLC plots for these two 
samples are also shown in Figure 2.11 where the complexity of these samples can 
be observed. These plots highlight the need for a two-dimensional separation as all 
the compounds would not be resolved using a single column and the methodology 
developed here delivers the capacity to resolve the complex samples.   
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Conclusions  
Due to developing technology, the vast quantity of available HPLC columns 
has given considerable choice when selecting columns for HPLC analysis [66]. 
When selecting columns for LC×LC, it is essential that their retention mechanisms 
are as different as possible. However, current methods to identify columns that fit 
this criteria are time consuming and not ideal for blind samples. Utilisation of 
LC/MS to compare columns has eliminated this problem as the unknown 
compounds are compared via their molecular mass. This allows columns to be 
blindly selected for unknown sample components without comparing each column 
pair individually. Even when the sample is known, injecting multiple standards for 
each column is still incredibly time consuming, whereas with the above method all 
standards can be combined, requiring each column to only be analysed once. This 
method not only allows for more columns to be compared in a shorter amount of 
time, but also spares the amount of sample and mobile phase required and the man 
power and wages for the time spent on the selection thus reducing the cost 
excluding of course the purchase price of a mass spectrometer.  
The use of the program OpenMS® enables successful selection of 
orthogonal columns for LC×LC. It was determined here that a first dimension 
diphenyl stationary phase and a C18 column in the second dimension was optimal 
for the separation of complex opiate extraction samples. An fcoverage of 0.48 was 
predicted by OpenMS® and algorithms designed in-house, with an actual 
separation fcoverage of 0.43 obtained after solvent mismatch was addressed with a 
counter gradient in the second dimension. The developed method was then applied 
to 68 opiate processing samples where average fcoverage values ranged between 0.24 
and 0.46, depending on complexity of the sample. For experiments requiring repeat 
analysis, the methods outlined here could allow for a comprehensive study to find 
the columns with the greatest orthogonality. 
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CHAPTER 3: 
OPIATE PROCESS STREAM ANALYSIS 
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Chapter overview 
The industrial process involved in extracting opiates from the opium poppy 
is quite complex and involves many steps. Of interest to Sun Pharmaceuticals is 
what components are present in each stage of the process, and which areas afford 
the most amount of chemical change in the manufacturing line. This chapter 
focuses on the analysis of the processing stream and the development of the 
platform technology to chemically map the manufacturing process. Principal 
Components Analysis (PCA) is employed after 2D-HPLC analysis of 65 samples 
from morphine, thebaine and oripavine streams. Mass spectrometry is then used to 
identify the masses that the PCA process identifies as the largest areas of change. 
The platform technology developed here enables the analysis of each stage of the 
manufacturing process or changes between different batches to be identified.   
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Introduction 
An important aspect of manufacturing pharmaceuticals is the elimination of 
impurities from the final product. Impurities can come in a variety of forms; as a 
starting material (including solvents and reagents), as a product of the 
manufacturing process or as a degradation product [71]. Impurities in 
pharmaceutical products are an issue that is closely monitored with strict 
regulations followed, as impurities could alter the effectiveness and safety of the 
product [173].  
Sun Pharmaceuticals extract opiates for use in medications, making it 
essential that the impurity levels are low. If impurities are high the batch fails, 
costing money and time, which has a negative impact on the business. Buyers of 
the opiates want to know the product they are getting is pure, leading to enquiries 
about unknown trace impurities. Of great interest to the manufacturers of 
pharmaceuticals is where the impurities come from and if there is a way to prevent 
them from forming or a way to eliminate them early in the process to ensure they 
don’t end up in the final product [174]. With improvements in the detection limits 
afforded by modern analytical chemistry instruments manufacturers can now 
determine impurities in ever diminishing concentrations. Due to having a better 
understanding of the composition of the products manufactures need to develop 
strategies to mitigate the impact of the impurities in the material produced. 
The use of a combination of 2D-HPLC, PCA and LC/MS has the potential 
to allow mapping of the opiate processing streams and discern what is changing at 
each stage. Principal components analysis (PCA) affords a deeper understanding of 
what is occurring in samples. This technique has previously been utilised in the 
chemical manufacturing of wine to inform vintners of the relationship between 
wine quality and the grapes physiochemical index [175]. It has also been used for 
the quality control of a medication in Belgium, where counterfeit pharmaceuticals 
are an issue. PCA was used to fingerprint medicine based on impurities and other 
components from the manufacturing process to compare legal and counterfeit 
profiles [176]. This highlights that this technique is very useful in chemical 
manufacturing and quality control.  
 55 
 
This is also important for different batches of poppy straw as growing 
opium poppies is subject to natural growing environments and each crop is likely 
to be affected in different ways. This can be caused by different geographical 
locations or even different cropping techniques employed on the farm. These 
factors can lead to varying levels of extracted compounds or the potential for new 
or differing impurities. This was noted in a study by Hopfer et al. where wine from 
different vineyards was analysed and found to differ in the elemental compositions 
[177]. The winery these wines were processed in also had an effect on the elemental 
composition [177]. In addition to this, new poppy hybrids are trialled and 
occasionally these new breeds could have a huge impact on the amount of opiates 
and or new impurities. In cases such as this, the platform technology developed 
here has the potential to make the analysis of any fundamental changes easier and 
allow monitoring of batches and crops before processing.  
  
 56 
 
Experimental 
Chemicals and samples 
Water was obtained from a Milli-Q filtration system (Merck Millipore, 
Victoria, Australia). HPLC grade acetonitrile (ACN) was purchased from Ajax 
Finechem Pty. Ltd. (Taren Point, NSW, Australia) and formic acid added at 0.1% 
to all mobile phases, was purchased from Hopkin & Williams Ltd, Essex, UK. 
Opiate processing stream samples were supplied by Sun Pharmaceutical Industries 
Australia Pty (Port Fairy, Victoria, Australia) that were extracted from Papaver 
somniferum following proprietary protocols. All solid samples were prepared at a 
concentration of 10 mg mL-1 in water prior to 2D-HPLC analysis and liquid 
samples were diluted by a factor of 10 with 10% acetic acid (VWR International, 
Fontenay-sous-Bois, France). All solid samples were prepared at a concentration 
of 1 mg mL-1 in water prior to LC/MS analysis and liquid samples were diluted by 
a factor of 100 with 10% aqueous acetic acid. Where these liquid processing 
samples fit into the process is illustrated in Figures 3.2 and 3.3. Other samples not 
in these diagrams include impurity standards and powdered samples. Because of 
the sensitive proprietary nature of the work, codes were used as-is to de-identify 
the samples to make publication of the data possible while not divulging proprietary 
information.      
Two-Dimensional High Performance Liquid Chromatography 
This was performed on the same instrument with the same method 
developed and outlined in Chapter 2. 
Principal Components Analysis (PCA)  
The 2D-HPLC separations were exported from the chromatography data 
system ChemStation as .AIA files before the peak information was extracted by 
first smoothing the raw data. Algorithms built in-house in the Wolfram 
Mathematica environment were used for all data analysis. The first and second 
derivatives of the curve were then scrutinised to find the start, end and maxima 
times for resolved, overlapping and shouldering peaks. After this the peaks were 
mathematically described and their area found by applying a combination of model 
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Gaussian curves to the data as illustrated in Figure 3.1 where Pap et al. [178] fitted 
model Gaussian peaks to a GC separation. To ensure the same compound is not 
spread over several first dimension fractions the peak profiles are compared in 
adjacent chromatograms. 
 
Figure 3.1: A representation of the fitting of model Gaussian curves to data by Pap et al. 
[178] for a GC separation of n-penthane and n-hexane. 
 
An algorithm designed in-house [65] using Wolfram Mathematica 10 
(distributed by SHI UK, Milton Keynes, England), processed all chromatograms in 
batch using the below peak picking parameters:  
 Least squares tuning parameter (λ): 1 × 106 
 Initial standard deviation for Gaussian fitting: 0.03 (min) 
 Savitsky-Golay window size: 3; polynomial order: 2 
 Minimum peak response threshold: 0.2 
 First derivative minimum response threshold: 5 × 10-4 
 Second derivative minimum response threshold: 1 × 10-5 
 90% overlap requirement to group peaks in adjacent 
chromatograms. 
 58 
 
Data pre-treatment was then performed in Mathematica 10 on the extracted 
2D-HPLC fingerprints with an in-house developed algorithm. In short this included 
peaks being reported as absolute multidimensional elution times after their 
retention times were analysed before peak retention times were binned at 6 second 
increments and the peak areas summed to define variables. Normalisation was 
conducted on these variables for chosen pairs of sample sets and the mean 
subtracted before a batch wise calculation of the first 2 principal components of the 
sample set pairs. Reconstruction of the multidimensional retention times for the 
loadings led to the development of the scores and loadings plots from principal 
components analysis using a covariance matrix. This two dimensional data was 
transposed to the bubble plot formation and all loadings were represented by the 
colours which can be used to either identify the positive and negative loadings or 
relate to the sample of interest. Throughout the text below this is described in each 
of the figure legends respectively  
     
Liquid Chromatography/ Mass Spectrometry (LC/MS) 
A Shimadzu LCMS-8040 Triple Quadrupole Liquid Chromatograph Mass 
Spectrometer (LC-MS/MS) was used for the analysis. The data in chapter 3 and 
chapter 4 were generated in MS/MS all other data was generated in single 
dimension MS. Positive ion polarity was used in conjunction with nitrogen drying 
gas (15 L min-1) and nitrogen nebuliser gas (3 L min-1). All processing stream 
samples (Chapter 3) were analysed with an injection volume of 1 µL and a flow 
rate of 0.5 mL min-1 for both methods. Method A (scaled to match first dimension 
LC×LC) was completed with an Agilent pursuit XRs 3 diphenyl column at an initial 
mobile phase of 15% ACN (85% water) that increased to 40% ACN over 8 minutes, 
increasing to 60% ACN over a further 4 minutes and was then isocratic (60% ACN) 
for a further 6 minutes. Method B (scaled to match second dimension LC×LC) was 
completed with a Phenomenex Poroshell C18 column at an initial mobile phase of 
10% ACN (90% water) that increased to 15% ACN over 8 minutes, increasing to 
60% ACN over a further 4 minutes and was then returned back to 10% ACN for a 
further 4 minutes. Chromatographic data were obtained and processed with 
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Shimadzu profiling solutions software with total ion count thresholds set to either 
1,000,000, 500,000 or 1,000 counts. 
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Results and discussion 
Figure 3.2 is an illustration highlighting where in the system the 18 samples 
obtained from Sun Pharmaceutical Industries morphine processing stream 
originated. Samples included here comprise of those from the main opiate line, the 
final product and the solvent waste streams. Likewise, Figure 3.3 illustrates the 
oripavine and thebaine manufacturing streams, where selected waste stream 
samples and the main processing line for both opiates have been provided for 
analysis.  
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Figure 3.2: Diagram of the samples from the morphine processing stream. 
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Figure 3.3: Diagram of the samples from the thebaine and oripavine processing stream. 
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Principal Components Analysis (PCA) 
Raw chromatographic data requires peak alignment before chemometric 
analysis can be performed due to minor variations in retention times. To align the 
2D-HPLC peaks from this data correlated optimised warping [179] was trialled, 
however it proved to be inefficient on a standard computer where it was unable to 
align 6 chromatograms with approximately 216,000 data points. In order to achieve 
a more rapid data analysis that is able to be performed by a standard computer, the 
data set was reduced by extracting the multidimensional retention times [65] and 
cumulative peak areas [180] to create characteristic sample fingerprints.  
Keeping the restrictions used to determine peak parameters constant, batch 
PCA was performed on comparisons of 89 sample pairs, each with triplicate 2D-
HPLC data. In this chapter two samples (G1527-028H and G1527-030O) have been 
selected as representative of all sample sets to show the developmental process of 
the techniques employed. A more in depth analysis of other samples of interest is 
included in the case studies in Chapter 4 where the significance of the chemistry at 
each stage of the processing stream is discussed. This chapter deals with the 
development of the analytical protocol. The samples selected are of interest due to 
their location in the oripavine processing stream, where G1527-028H comes 
directly before the target compound is removed and G1527-030O is the spent 
stream after the removal of oripavine.  
In Figure 3.4, the 2D-HPLC data (sample G1527-030O) has been illustrated 
in two distinctive ways to highlight the value of the information that can be gained 
from these plots. The most common (Figure 3.4a) way of illustrating the data is via 
a contour plot, where the purple represents the background, the red signifies a large 
intensity peak and the white dots indicate the peak maxima. A disadvantage of this 
plotting technique is the ability to appropriately visualise the third dimension to the 
data, the peak intensity. This occurs because compounds that are less-absorbing 
may be lost when scaling the data or large peaks lose their detail when trying to 
visualise these smaller peaks. An alternative way of visualising this data is a bubble 
plot developed specifically for this project where a characteristic fingerprint was 
produced by picking the key chromatographic features. The bubble plot allows the 
peak height to be visualised by the diameter of the circle, where the centre is the 
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peak maxima at the corresponding first and second dimension retention times (x- 
and y-axis, respectively). The diameter of the bubble in Figure 3.4b is proportional 
to the relative peak area and they have been normalised between 0 and 1. It is also 
important that the size of the bubble is only indicative of the height of the peak and 
does not convey the resolution of the separation based on overlapping bubbles. 
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A)                                                                                                                                                       
 
B) 
 
Figure 3.4: Illustrative 2D-HPLC chromatograms of sample G1527-030O (replicate 1). 
A) Contour plot with peak intensities from 1 to 75 amu is represented and is scaled from 
purple (low) to red (high), B) peak maxima are located at the centre of the bubbles and 
the peak intensities are represented by the bubble diameter, which have been normalised. 
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The sample or variable matrix is required to be rectangular for the principal 
components calculation. This required the use of the binning technique, which is 
where the separation space is broken up into square ‘bins’ [155]. The information 
can then be characterised by the amount of bins the data points occupy. This was 
illustrated in Chapter 2, where for example Figure 2.10 shows grey squares that 
represent the bins occupied by data points and the white area are those that are not 
occupied. Using this method, the retention data was divided evenly in 0.1 minute 
intervals for the 90 minute run time to overcome the differing number of peaks 
detected in each chromatogram. By creating the rectangular sparse matrix, the 
analytes with slightly differing retention times were aligned thus eliminating the 
need to align the peak retention data prior to chemometric analysis. Prior to binning 
the data, it was normalised and the mean from each bin’s cumulative peak area was 
subtracted. Principal components analysis was completed with randomised 
triplicate 2D-HPLC analysis of each sample in batch using a covariance matrix and 
scores plots of the first two principal components were created along with their 
corresponding loadings plots. 
Figure 3.5 displays the PC1 × PC2 scores plots for the samples G1527-028H 
and G1527-030O, where 67.4% of the sample variance is accounted for in PC1 and 
89.4% by the 2 components. A clear distinction can be noted between the two 
samples with the G1527-028H replicates grouped in the first quadrant of PC1 and 
PC2 replicates of G1527-030O in the second quadrant. One replicate of G1527-
030O is not grouped tightly with the other two, however this can be explained by 
this sample being of a solvent base, where some solvent remained in the sample on 
the first replicate thus affecting this result. Despite this, it can be observed that there 
was a large distinction present in PC1 between these two samples with a large 
majority of variance covered by the first two principle components.      
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Figure 3.5: PC1 × PC2 scores plot of G1527-028H and G1527-030O samples. 
 
Indications of what variables are responsible for the bulk variance between 
samples were observed by the loadings of the principal components. For this 
analysis the loadings of the first two principal components were converted into a 
multi-dimensional representation of the data, which is illustrated by the bubble 
plots in Figure 3.6. The centre of the bubble corresponds to the coordinates of the 
multidimensional retention time while the absolute normalised loading on each 
principal components equals the radius of the bubble. A larger impact on the change 
that peak had on the overall discrimination between groups on the scores plot is 
signified with a larger diameter bubble. To simplify, the more significant the 
change in peak area, the larger the corresponding bubble). The colour of the bubbles 
is also significant as they indicate which sample is responsible for an increasing or 
decreasing change in average cumulative area, where blue indicates a larger 
average area of the peak in G1527-028H and red indicates the peak in G1527-030O 
had a larger average area. 
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A)  
B)  
 
Figure 3.6: PCA loadings of A) PC1 and B) PC2 for the samples G1527-028H and 
G1527-030O. A blue bubble indicates a larger average area in the 028H samples, and a 
red bubble indicates the 030O samples were more concentrated. 
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The comparison of these two samples indicated from the loadings of PC1 
and PC2 that the most variation between samples occurs in the lower left hand 
section of the multidimensional separation. The high concentration compounds 
would most likely be highly polar in the aqueous streams, but as the pH is adjusted, 
polar compounds may become neutral and crystallise out. As such they would 
demonstrate the most significant change in relative area. In each of the loadings 
plots, the bubbles were normalised separately so the PC1 and PC2 changes cannot 
be directly compared, for example the largest bubble in the second principal 
component does not necessarily mean that there was a greater impact than a smaller 
first principal component and vice versa. The biggest change in PC2 was caused by 
a peak eluting at 72 minutes in the first dimension and 3.17 minutes in the second 
dimension. The data for this peak (72, 3.17 minutes) of the triplicate 
chromatograms of G1527-030O are presented in Table 3.1, in addition to the 
loadings of this peak when compared to G1527-028H. The loadings values of both 
principal components were similar, but this smaller value was more significant 
compared to the other loadings in PC2 compared to PC1. Due to this peak having 
a greater influence on PC2 in the scores plot it was likely that the relatively large 
value of the standard deviation (σ = 2.289) of these areas was causing most of the 
spread on this axis in Figure 3.6. 
Table 3.1. Replicate fingerprint data for multidimensional chromatograms 
of G1527-030O. 
Replicate tR,1 tR,2 Area 
Loading PC1 
(Rep 1-3) 
Loading PC2 
(Rep 1-3) 
1 72 3.160 7.812 -0.0841 -0.06394 
2 72 3.164 2.781   
3 72 3.165 3.151   
 
 To find if the molecules were being formed by the manufacturing 
process or whether impurities present at the end of each stage were from the opium 
poppy itself, these loading plots from the 2D-HPLC fingerprints were interrogated. 
Representative chromatograms of before (G1527-028H) and after (G1527-030O) 
the key compound oripavine is extracted are illustrated in the contour plots in 
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Figure 3.7, where the PC1 loadings are overlayed. It was postulated that if 
differences between these samples were from the poppy biomass extraction alone, 
the resultant changes in these chromatograms would be peaks that are missing from 
G1527-030O that remain in G1527-028H, which would be represented by yellow 
bubbles only. However, the biggest changes between these two chromatograms 
were the presence of new compounds throughout the G1527-030O chromatogram 
as highlighted by green bubbles in Figure 3.7. The G1527-030O sample was taken 
from a reaction vessel that had been under storage for several days between cycles 
and thus kept at atmospheric temperature and pressure. This would suggest that 
new compounds seen in this sample are a result of degradation or oxidation 
reactions taking place in the vessel and thus confirm that changes are taking place 
during the manufacturing process. To date, Sun Pharmaceuticals have done very 
little work in this space and the work presented in this thesis has enabled the 
company to further refine its priorities for sample interrogation. 
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A) 
 
B) 
 
Figure 3.7: Overlay of PC2 loadings on 2D-HPLC chromatograms of A) G1527-028H 
and B)G1527- 030O (replicate 1). A yellow bubble indicates a larger average area in the 
G1527-028H samples, and a green bubble indicates the G1527-030O samples were more 
concentrated. 
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An indication that this protocol is working well can be determined by the 
larger yellow disk observed in Figure 3.7 from the G1527-028H sample, this 
identifies the removal of oripavine before the next sample (G1527-030O) the key 
step at this point of the process. This reiterates some features that were expected 
however other aspects such as the formation of new compounds in the latter sample 
are an important finding in the manufacturing process. This is significant for quality 
control and to understand what is occurring at each step of the process. If new 
compounds are formed at stages such as this and then become problem impurities 
in the final product, it is possible that it can be addressed by not allowing the batch 
to be exposed for as long. To enable the identification of the compounds causing 
major changes in between processing steps, LC/MS can be utilised to pinpoint the 
responsible masses.   
 
Mass Spectrometry 
Mass spectrometry was utilised to develop an in depth understanding of the 
peaks that were responsible for the most amount of change between process 
samples. It was anticipated that between G1527-028H and G1527-030O there 
would be a significant amount of change to the amount of oripavine present due to 
the step in between these two samples being the removal of this compound. To fully 
validate this, a standard of oripavine was also analysed by 2D-HPLC and LC/MS 
as shown in Figure 3.8. Due to the significantly greater sensitivity of the mass 
spectrometer in comparison to the UV-vis detector, the oripavine was too 
concentrated in all three samples. Thus, when the mass spectrometry data is 
observed the change in oripavine was not noted as a big change as in all three 
samples the detector recorded a maximum total ion count for this compound. This 
however is significant as it highlights that although the bulk of oripavine is 
precipitated out at this step, there is still a large portion carried over to the mother 
liquors that continue on in the process. 
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Figure 3.8: 2D-HPLC contour plot of a supplied oripavine sample (G158-131A). 
 
Whilst oripavine is expected to change, other unknown components of the 
sample also differ, requiring the use of a combination of 2D-HPLC, PCA and mass 
spectrometry to identify those compounds. The areas responsible for the greatest 
change are presented in Table 3.2, in conjunction with the first and second 
dimension retention times. These retention times can then be matched to the scaled 
LC/MS data to locate what compounds correspond to these changes and the signal 
intensities can then be compared to identify the mass of the responsible molecule. 
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Table 3.2. The PCA loadings (Figure 3.5A) scores for the comparison of 
G1527-028H and G1527-030O.    
First dimension RT 
Second Dimension 
RT 
PC1 loadings 
scores 
24 0.85 0.243382 
24 1.05 0.196234 
28 0.65 -0.126360 
36 0.65 -0.147570 
32 1.05 -0.458970 
32 0.85 -0.492530 
28 0.55 -1.000000 
 
The positive PC1 loadings scores indicate the compound has a greater 
average area in G1527-028H than in G1527-030O and the negative values indicate 
a greater presence in the latter, as visualised in Figure 3.5.  From these values and 
coordinates the LC/MS data was consulted to identify the masses responsible for 
the changes (Table 3.3). 
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Table 3.3: Masses corresponding to first dimension retention times 
identified by PCA (PC1).    
Ion m/z Ion RT 
(mins) 
Adj. RT 
(mins) 
G1527-028H 
(Ion counts) 
G1527-030O 
(Ion counts) 
314.19 4.80 24.02 1322110 0 
617.30 4.94 24.68 4101544 3714015 
298.17 5.02 25.10 20000000 20000000 
299.19 5.02 25.10 20000000 20000000 
314.19 5.68 28.38 0 1121306 
329.20 5.71 28.57 1303501 1699879 
318.15 5.72 28.59 0 1462715 
328.18 5.73 28.65 7626469 8626498 
370.18 5.79 28.94 2270866 2851843 
330.20 5.81 29.06 20000000 20000000 
344.22 6.45 32.23 7411381 14269454 
328.18 6.54 32.70 17465896 20000000 
329.20 6.55 32.73 3215862 5032537 
344.23 6.60 33.02 20000000 20000000 
345.24 6.62 33.12 20000000 20000000 
312.19 7.22 36.09 18173297 20000000 
316.19 7.22 36.12 0 1353942 
314.23 7.23 36.13 3935946 7778106 
313.21 7.23 36.17 3725287 6779475 
342.21 7.41 37.06 3828494 4116965 
 
In this chapter, the methodology has been shown to be effective at 
identifying key features of the data at hand. To realise the full potential of this 
methodology, application to the entire processing streams of morphine, thebaine 
and oripavine has been performed in Chapter 4 to establish changes in a chemical 
system that encompasses numerous steps and chemical environments.      
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Conclusions 
A platform technology has been developed here for the mapping of opiate 
extraction streams that will allow for a greater understanding of changes along the 
process. A multidimensional separation addressed the complexity of the process 
samples and achieved the necessary resolving capacity not afforded by 
conventional HPLC. These two-dimensional HPLC fingerprints were used in 
conjunction with PCA loading plots to highlight key differences between pairs 
of sample sets taken from the Sun Pharmaceuticals morphine and thebaine 
extraction process. It was found that relative changes between two sets of samples 
could be identified by the analyst using bubble plots of loadings overlayed on a 
contour representation of the data and relative peak area could be labelled as either 
increasing or decreasing. The major changes could then be pinpointed using scaled 
LC/MS, to find the mass of the peaks of interest.    
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CHAPTER 4: 
APPLICATION OF PLATFORM TECHNOLOGY TO 
MONITOR COMPONENTS OF INTEREST 
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Chapter overview 
This chapter applies the methods previously described in Chapters 2 and 3 
to a series of case studies based on monitoring key compounds of interest within 
the opiate processing streams. Segments of the processing stream where the key 
differences between the samples were observed are investigated to highlight the 
impact that each stage of the process has on the chemistry of the sample matrix. 
This chapter highlights the utility of this type of methodology to solve tangible 
process chemistry problems and builds capacity for the process owners to make 
timely informed decisions.   
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Introduction 
The opiate processing stream is complex, with many steps required in order 
to extract and purify opiates on a large scale. These steps can be as simple as being 
held in a holding tank or as complex as large column separations. In-process control 
tests at each stage of drug extraction are important to the final quality of the 
intermediate or API. As such, it is important to know what is occurring along the 
process in case of an abnormality or to track trace impurities to ensure the quality 
of the drugs [181]. Manufacturers of pharmaceuticals must adhere to the strict 
guidelines set out in the ICH-Q3A of 2006 [182] and comply to the relevant 
pharmacopeia monographs. The ICH-Q3A specifically targets the regulation of 
impurities in new drug substances to ensure all known and unknown drug 
impurities are reported correctly and meet safe standards [182, 183]. Currently a 
threshold for impurities and degradation products is in place for active 
pharmaceutical ingredients (API) with a maximum of 0.1% unknown compounds 
allowed [71]. However, as sensitivity of detection methods improve it has a flow 
on effect to the customer of these products as they begin to question these trace 
impurities, thus applying pressure to the manufacturer to know the identity of each 
of these unknown compounds.       
Quality critical attributes (QCA) and quality critical parameters (QCP) are 
both important complimentary concepts. The quality critical attributes are 
characteristics that could potentially impact the safety and effectiveness of the 
product [184] and as such quality critical parameters are put into place by 
companies to ensure the attributes are met. To ensure effective quality critical 
parameters are in place an understanding of what may affect the impurities is 
required and identification of compounds (e.g. structure) would help with this 
insight.   
Of further interest is where these compounds originate and what is lost and 
gained at each step of the process, to determine if impurities of interest are a product 
of the manufacturing stream, introduced with raw materials or solvents, or if they 
come from the key starting materials, i.e. opium poppy, itself. This also has the 
potential to be complex as the variety and growing conditions of the crops have the 
potential to influence the type and quantity of impurities, and as such highlights the 
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importance of having robust analytical monitoring that can detect and measure 
these changes. Currently there are many molecules of interest to Sun 
Pharmaceutical Industries Australia that to date have only been identified by their 
molecular weight. While the list is extensive, for this thesis the molecules with a 
molecular weight of 285 amu, 297 amu and 622 amu have been identified as 
significant impurities in their processing streams by Sun Pharmaceuticals. It is of 
great interest to know where within the process stream these impurities originate 
for Sun Pharmaceuticals to develop informed and subsequently targeted 
elimination or mitigation protocols.  
Molecule of Interest 1 (285 amu) 
The molecule with a mass of 285 amu is of great interest to Sun 
Pharmaceuticals as it has been observed as an impurity for a long time in the 
morphine processing stream and is present in the final product. Interestingly 
morphine also has a molecular mass of 285 amu and it has been proposed that it is 
likely to be an isomer of morphine. Isomers are typically difficult to separate and 
this may explain why it is such a persistent impurity in the morphine line.  
Molecule of Interest 2 (622 amu) 
The molecule with a mass of 622 amu is also a key component, more 
structural elucidation including NMR spectroscopy has been performed on this 
molecule and the compound has been identified by Sun Pharmaceuticals as O-
Methylsomniferene (O-M-Somniferene), an asymmetric dimer of thebaine (Figure 
4.1). As such this compound may possess similar chemical attributes to thebaine 
causing it to be persistent within the processing stream. This compound has 
historically been a problem in the thebaine processing stream and as such it is of 
great interest where this compound emanates from in order for the process owners 
to limit its production or improve on its removal. 
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Figure 4.1: Structure of O-M-Somniferine.   
  
Molecule of Interest 3 (297 amu) 
A further impurity of both the thebaine and oripavine processing stream 
(due to the same starting point/product) is the molecule with a molecular mass of 
297 amu, previously determined to be nor-thebaine (Figure 4.2). Interestingly, this 
impurity has the same molecular mass as oripavine and due to its potential as an 
isomer is of great interest to the company. Further, nor-thebaine is used as a 
precursor to pharmaceutical intermediates such as those used for buprenorphine 
[185]. Understanding its formation either in the plant or process may provide a 
method for simple and cheap production over existing synthetic routes.  
 
Figure 4.2: Structure of Nor-thebaine. 
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The use of in silico optimised 2D-HPLC has been shown to be an effective 
way of resolving isomers and recent work, supplementary to this thesis, has shown 
the application of this process to the resolution of ephedrine and pseudoephedrine 
in methamphetamine seizure samples [186]. In short, this work was developed for 
the interrogation of methamphetamine samples including model, real world seizure, 
and laboratory synthesised samples. The protocol used Drylab® software to rapidly 
identify the optimum separation conditions from a library of chromatography 
columns. The optimum separation space was provided by the Phenomonex Kinetex 
PFP column (first dimension) and an Agilent Poroshell 120 EC-C18 column 
(second dimension). To facilitate a rapid 2D-HPLC analysis the particle packed 
C18 column was replaced with a Phenomenex Onyx Monolithic C18 without 
sacrificing separation performance. The Drylab® optimised and experimental 
separations matched very closely, highlighting the robust nature of HPLC 
simulations.  
A fully comprehensive two-dimensional separation was completed with a 
total analysis time of 115 minutes, the separation is illustrated in Figure 4.3. The 
retention times predicted by DryLab® are shown by the white circles, which have 
been overlaid on the actual two-dimensional separation (Figure 4.3). 
 
Figure 4.3: Overlaid DryLab® and actual two-dimensional separation of the model 
methamphetamine seizure sample. 
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After training the software with data from separations occurring over 2 
different gradient durations the simulation was able to extrapolate 2 variables (i.e. 
S and kw) for each peak that are required to predict the retention time with varying 
gradient durations. DryLab® is able to simulate the retention profile of a complex 
separation matrix with a single step (linear) gradient, or by adding multiple steps; 
a 4 step gradient is presented here. When this process is done to optimise each 
retention dimension individually a 2D-HPLC retention map can be extrapolated 
and the final multidimensional simulation is predicted. 
This is one of the early points that in-silico software has been used to predict 
a two-dimensional separation of methamphetamine samples and indeed 
forensically relevant samples at large. This is of great significance for the 
development of 2D-HPLC protocols, a process that historically takes considerable 
time. The total method development time for the separation presented in Figure 4.3 
was less than two hours with in-silico aided optimisation. This is significantly less 
than the time required for typical two-dimensional separation optimisation that 
normally requires many individual sample injections [153]. The results of 2D-
HPLC separation prediction was impressive as all components of interest were 
closely matched (Figure 4.3). This is not a trivial outcome due to the complex 
nature of the separation mechanisms involved allowing the user to have high 
confidence in the in-silico prediction. The power of 2D-HPLC observed in this 
work is directly applicable to the challenge of identifying key components in 
complex process chemistry samples. The work in this chapter takes this technology 
a step further by incorporating the first application of PCA to two-dimensional 
chromatographic data. 
 
  
 84 
 
Experimental 
Case studies  
The techniques previously described in Chapters 2 and 3, have been applied 
to samples from select sections of the process stream. Initially, 2D-HPLC was 
performed on each of the samples and compared as mentioned in Chapter 2 and 
subsequently analysed using Principle Components Analysis (PCA) as described 
in Chapter 3. The samples were then analysed with mass spectrometry in a method 
scaled to match the first and second dimension of the 2D-HPLC, as previously 
described in Chapter 3. The areas of change were identified from the PCA plots 
and all mass spectral peaks within the corresponding retention times were 
compared to determine which compound was the cause of the greatest changes in 
between the respective steps of the process stream. Specific points of interest were 
examined using these methods and reported as individual cases defined by the list 
below.  
Case 1: G1527-027N, G1527-027O and G1527-027G. 
Case 2: G1527-027L and G1527-027M  
Case 3: G1528-028C, G1527-028D and G1527-028H 
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Results and discussion 
Molecules of interest 
The opiate processing stream contains many molecules of interest to both 
the company and its customers. Three masses of interest have been focused on in 
this chapter, where they have been mapped throughout all 81 opiate processing 
stream samples in the main line, waste lines and crude impurity standards. The 
presence of the molecules at 285 amu, 297 amu and 622 amu are illustrated through 
the processing stream in Figures 4.4 and 4.5. 
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Figure 4.4: Morphine processing streams with masses 622 (present when red) and 285 
(present when blue). 
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. 
Figure 4.5: Thebaine and oripavine processing streams with masses 622 (preset when 
red) and 297 (present when yellow). 
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Molecule of interest 1 (285 amu)   
Morphine has a molecular mass of 285, however there are isobaric 
components present throughout the processing stream that have the same mass and 
are considered impurities. One such compound of this mass is of great interest as it 
is present in the final morphine product and to date the structure is unknown. The 
company are interested in whether the peak was an impurity extracted from the 
opium poppy or if it is a product of the processing stream, to determine if it is 
something that could be controlled or eliminated. From the LC/MS data of all the 
process samples, the impurity was found in the first extraction (G1527-027A) and 
continued through the main stream to the CPS morphine (Figure 4.4). This indicates 
that the steps taken along the process have not been effective in removing this 
impurity. The powdered samples, CPS-M (G1558-131D) and technical morphine 
(G1558-131B) were both tested where the latter is a purified form at 94% compared 
to 79%. The impurity with a molecular weight of 285 amu was only present in the 
CPS morphine (G1558-131D). In the thebaine processing line it was found to only 
be present in two samples tested, G1527-030N and G1527-030O which are both at 
points along the stream where concentration occurs leading to the possibility that 
the impurity is minute in the rest of the stream but becomes noticeable via mass 
spectrometry when the stream is concentrated up. 
The fragmentation pattern of compounds with the same mass can be used 
to elucidate the chemical structure. The two compounds at m/z 286, as shown in 
Figure 4.6 were identified by mass spectrometry and have different fragmentation 
patterns and chromatographic retention times that vary by approximately two 
minutes. The first peak is consistent with the fragmentation pattern of morphine, 
however the second is significantly different indicating that it is a structural isomer.  
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Figure 4.6: Mass spectral fragmentation pattern of a) morphine and b) the unknown impurity of the same mass. 
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To further characterise this compound and the following two, NMR 
spectroscopy needs to be performed however due to the complex nature of these 
samples the target compounds required separation from the other components in 
the sample to enable structural elucidation. This was attempted by utilising a one-
dimensional HPLC separation with the previously discussed diphenyl column on 
an analytical scale. Using an Agilent fraction collector after the detector, target 
peaks were collected on a time based scale, the mobile phase evaporated and then 
reconstituted with deuterated methanol before NMR analysis. A portion of the 
fractions was taken for direct injection mass spectrometry to confirm the collected 
peaks were the target compound. Whilst this was confirmed the lack of sensitivity 
of the NMR meant the peaks could not be characterised, even after in excess of 100 
fractions were collected and combined. Semi-preparative HPLC was also trialled 
to increase the amount of sample that could be utilised however due to poor 
chromatography, this idea was also abandoned. Due to the difficulties with 
collecting enough of the target compound an alternate way to concentrate the 
impurity is required however this is now beyond the scope achievable here.   
Molecule of interest 2 (622 amu) 
The second mass of interest is 622 amu which corresponds to the compound 
O-M-Somniferine (Figure 4.1). This mass was investigated as it is a known 
impurity of the thebaine processing stream, however the results found with LC/MS 
also identified a mass corresponding to the m/z 623 molecular ion in the morphine 
samples. This is a mass not currently looked for in the morphine processing line, 
however it is postulated to be an asymmetric dimer of thebaine. The MS/MS data 
showed thebaine in the fragmentation pattern and as such this supported the 
proposed compound assignment. As illustrated in Figure 4.4 this compound is in 
the first sample extract from the poppy straw pellets and continues through the main 
processing stream until the caustic wash where it is expelled into the recycled 
solvent waste. This suggests that it originates in the raw product and is efficiently 
extracted under the conditions afforded by the process. Finding this impurity in the 
recycled solvent waste may also have implications on the process as the impurity 
is being reintroduced into the stream towards the start of the process, potentially 
leading to an increased concentration throughout the batches. This highlights the 
importance of tracking impurities as this is potentially a sampling point that can be 
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monitored to ensure the concentration of the impurity is not increasing significantly 
and possibly causing issues in the extraction process.   
This compound is also observed in the thebaine stream, only emerging at 
G1527-030A, the rich solvent after thebaine and oripavine are separated (Figure 
4.5). This compound stays in the stream despite caustic impurity washes and is 
removed at the point of the acid washes. During the acid washes the compound is 
absent from the main stream but appears in each of the sequential downstream acid 
washes. It is postulated here that this occurs due to the main stream being 
significantly more dilute than the acid wash sample, where the compound is 
gradually washed into these lines.  
At the first acid wash stage (G1527-O30G) that uses organic acid an isomer 
of m/z 623 is observed denoted by two peaks of the same mass with different 
retention times. This highlights the importance of the concentration steps as the 
second isomer is only observable when concentrated downstream. As such for any 
thorough investigations into these compounds that Sun Pharmaceuticals may need 
to do for a client, concentration of the sample streams prior to the acid wash would 
be required. Alternatively, this isomer could be forming at this stage due to a 
chemical reaction induced by a lowering of the pH.  
At the third acid wash stage using mineral acid (G1527-O30K) the original 
isomer of m/z 623 was no longer observed. This indicates that the efficiency of the 
organic acid wash was sufficient to remove the primary m/z 623 isomer. Further, 
the mineral acid washes completely remove the second m/z 623 isomer from the 
process stream. This work highlights the issues associated with compounds of the 
same mass that are observed only at certain points in the stream and this technology 
allows process owners to carefully monitor these compounds. 
Molecule of interest 3 (297 amu) 
The third mass of significant interest is 297 amu, which corresponds to the 
impurity nor-thebaine (Figure 4.2). This compound is a known impurity in the 
thebaine stream and shares the same mass as oripavine and a further unknown 
compound present primarily in the morphine stream. Due to its presence in the 
combined thebaine and oripavine stream, this impurity is of particular interest. The 
impurity was not detected in the morphine stream, however its presence was traced 
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through the thebaine and oripavine stream as illustrated in Figure 4.5 denoted by 
yellow highlights.   
This impurity elutes at 6.9 minutes and as such elutes after oripavine. From 
this the impurity is first present at sample point G1527-028L, after the opiates have 
been extracted from the straw with water miscible solvent and subsequently heated 
to remove the solvent. The impurity is then present in the main processing stream 
until the acid washes. During the organic acid treatment the impurity is present in 
both the washes and the process stream. At the mineral acid stage the remainder of 
the compound is extracted out. In the sample G1527-030G, this compound is found 
to be the most concentrated, exceeding the detection capabilities of the LC/MS. 
This sample is the first acid wash to form aqueous rich extract and as such is more 
concentrated. This compound is also found in the rich aqueous oripavine and the 
resulting mother liquor. This shows the capacity to gain information on quality 
from the concentration stages of the processing streams. 
Case 1: G1527-027N, G1527-027O and G1527-027G. 
Case 1 is from the morphine processing stream and focuses on the samples 
G1527-027N, G1527-027O and G1527-027G. G1527-027N (see Figure 4.4) is 
fresh rich aqueous caustic extract. G1527-027O directly follows G1527-027N and 
is the rich aqueous composite. This is then subjected to a crystallisation and 
precipitation step, where CPS morphine is recovered and G1527-027G is the 
mother liquor left from this process (Figure 4.4).  
The PC1 × PC2 scores plots for G1527-027N and G1527-027O were first 
consulted to determine the sample variance. Figure 4.7 illustrates that 63.5 % of the 
sample variance is accounted for in PC1 and 92.3 % by the first two components.   
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Figure 4.7: PC1 × PC2 scores plot of G1527-027N and G1527-027O samples. 
 
The loadings plot for G1527-027N and G1527-027O were compared and 
the changes investigated. It was found that there were significant changes between 
these two samples with eight major differences. This is illustrated in Figure 4.8 and 
the retention times of these changes are shown in Table 4.1. 
 
Figure 4.8: PC1 loadings plot for G1527-027N against G1527-027O from 2D HPLC 
analysis. 
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Table 4.1: The top eight PC1 loading scores for G1527-027N and G1527-027O 
First Dimension 
RT 
Second Dimension 
RT 
PC1 Loadings score 
24 0.5 1.000 
28 0.8 0.479 
28 1.0 0.466 
32 3.3 0.172 
24 0.6 0.172 
72 3.1 0.165 
32 0.6 0.144 
80 3.3 0.105 
 
These retention times were then compared to the profiling solutions LC/MS 
data, where an ion count threshold of 1,000,000 was utilised to focus on the 
important large changes. It is important to note that the focus here was placed on 
the larger changes in order to test the protocol and that for broad application 
individualised assessment of the mass spectral thresholds will need to be made. As 
the technology developed here gets greater use an informed peak count threshold 
will be required however the threshold described here was shown to be sufficient. 
Care will need to be taken for application of this to other sample types beyond 
opiates which may possess lower mass spectral ionisation efficiencies. The changes 
are highlighted in Table 4.2  
Table 4.2: Pseudoolecular ion mass to charge ratios, total ion counts and retention 
times for the peaks with significant changes observed in the loadings plots for 
G1527-027N and G1527-027O respectively (1,000,000 threshold).  
Ion m/z Ion RT 
(mins) 
Adj. RT 
(mins) 
G1527-027O (Ion 
counts) 
G1527-027N 
(Ion counts) 
344.23 5.69 28.44 4129200 2329157 
329.20 5.71 28.57 1171678 0 
328.18 5.73 28.65 5010879 5270546 
194.10 6.41 32.04 1507660 0 
328.18 6.54 32.70 19225078 14066945 
329.20 6.55 32.73 4228279 2858543 
314.22 6.58 32.88 8123023 5099602 
338.36 16.06 80.31 1408922 1634005 
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The changes at a retention time of 28.44 and 28.57 minutes (Figure 4.8) 
correspond to the molecular ions m/z 344 and m/z 329 respectively. The mass to 
charge ratio is consistent with the compound laudanine (Figure 4.9) which is readily 
known in the opiate steam as it is a biosynthetic intermediate [187] and as such this 
was compared to its impurity standard (G1527-034M), an in house fractionated 
sample of laudanine (Figure 4.9). These standards are routinely separated and 
concentrated within the Sun Pharmaceuticals R and D laboratory at Port Fairy. The 
bespoke nature of these materials makes it difficult to find commercial standards 
and as such it is important to note that these standards typically vary in their 
impurity levels and care needs to be taken when using them. Interestingly the 
laudanine standard was found not to match the retention time of 28.44 minutes 
appearing approximately 5 minutes earlier. This implies that the molecule is likely 
to be similar to laudanine including its interaction with the diphenyl stationary 
phase. 
 
Figure 4.9: Structure of Laudanine.  
 
As mentioned previously, an ion count threshold of 1,000,000 was set, in 
this study to limit the data size to a reasonable and workable amount, however if 
necessary the threshold may need to be adjusted to enable a thorough investigation 
of the changes of interest to other sample sets. To visualise the implications of a 
significant adjustment to the ion count threshold a study was performed on the same 
data set as presented in Figure 4.8 with a new threshold of 500,000 ion counts. The 
molecular masses of the compounds responsible for the major changes are 
presented in Table 4.3. 
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Table 4.3: Molecular ion mass to charge ratios, total ion counts and 
retention times with the peaks with the most observable change in PC1 loadings for 
G1527-027N and G1527-027O (500,000 threshold) 
Ion m/z Ion RT (mins) 
Adj. RT 
(mins)
G1527-027O 
(Ion counts)
G1527-027N 
(Ion counts)
344.22 5.68 28.40 4129200 2329157 
345.24 5.69 28.46 998658 0 
329.20 5.72 28.60 1171678 1139468 
328.18 5.73 28.65 5010879 5270546 
194.10 6.41 32.04 1507660 1044668 
328.18 6.54 32.70 19225078 14066945 
329.20 6.54 32.72 4228279 2858543 
360.20 6.56 32.82 862555 772804 
314.22 6.57 32.86 8123023 5099602 
330.21 6.57 32.86 746301 0 
315.21 6.59 32.93 1962637 996321 
171.14 14.40 72.00 543210 0 
228.21 14.43 72.17 693820 0 
540.44 14.50 72.47 790429 680697 
334.21 14.50 72.48 0 582340 
304.22 14.54 72.71 856586 1004728 
378.26 14.57 72.86 753073 785251 
228.20 14.58 72.92 568811 0 
436.29 16.09 80.44 694525 625891 
 
As can be observed from Table 4.3, the change in threshold allowed changes 
at 72 minutes to be identified. This highlights the importance of adjusting the 
threshold to allow a better understanding of changes if no masses are noted at the 
retention times identified by PCA analysis.  
The next sampling point of interest to case study 1 is G1527-027G, which 
directly follows G1527-027O (Figure 4.4). Figure 4.10 describes the loadings plot 
for the samples G1527-027G and G1527-027O. As can be noted from the plot a 
large amount of change can be observed between 16 and 17 minutes in the first 
dimension. This is also observed in the PCA loadings scores in Table 4.4, where 
the seven significant changes in the samples are shown with the biggest change 
observed at a retention time of 16 minutes.   
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Figure 4.10: PC1 loadings plot for G1527-027G against G1527-027O from 2D HPLC 
analysis.   
 
Table 4.4: The seven PC1 loading scores for G1527-027G and G1527-027O 
First Dimension 
RT 
Second dimension  
RT 
PC1 loadings 
score 
16 0.4 1.000000 
16 0.3 0.779080 
36 2.7 0.166485 
16 0.5 0.102417 
32 0.5 0.081450 
56 0.3 0.076003 
24 1.1 0.070652 
 
The mass spectral peaks were compared to the known retention time 
differences noting that this was performed at an ion count threshold of 1,000,000. 
The mass spectral peaks that were identified at these retention times are shown in 
Table 4.5, where the values highlighted in yellow are those that produced the most 
significant change at that respective retention time. 
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 Table 4.5: Molecular ion mass to charge ratios, total ion counts and 
retention times with the peaks with the most observable change in PC1 loadings for 
G1527-027G and G1527-027O. The highlighted rows indicate the values 
associated with the most notable changes corresponding to table 4.4.  
Ion m/z Ion RT Adjusted 
RT 
Ion Count 
G1527-027G 
Ion Count 
G1527-027O 
324.11 3.29 16.45 0 6651041 
286.16 3.31 16.55 20000000 20000000 
308.18 3.31 16.56 0 20000000 
325.13 3.33 16.63 0 1421907 
669.25 3.33 16.63 3807454 0 
268.14 3.33 16.64 2387128 19796688 
287.17 3.33 16.64 20000000 19350048 
593.27 3.33 16.64 0 2963348 
288.20 3.33 16.66 8296774 12787382 
192.12 3.34 16.70 20000000 0 
193.16 3.34 16.72 8179070 0 
316.18 3.36 16.78 1174037 0 
302.18 3.36 16.79 19904082 0 
603.30 3.36 16.79 11272815 0 
604.20 3.36 16.79 4500447 0 
240.16 3.36 16.80 7938151 4955320 
318.16 3.39 16.94 7439495 0 
208.13 3.39 16.96 3024467 0 
314.19 4.80 24.02 1429778 0 
490.25 4.87 24.34 1725044 0 
194.10 6.41 32.04 6184907 1507660 
344.22 6.45 32.23 5324913 0 
328.18 6.54 32.70 20000000 19225078 
329.20 6.55 32.73 4971785 4228279 
360.18 6.55 32.77 7421490 0 
378.18 6.56 32.81 2050925 0 
314.22 6.58 32.88 20000000 8123023 
316.19 7.22 36.12 1276425 0 
314.23 7.23 36.13 2151253 0 
329.23 7.23 36.17 9909379 2319867 
328.21 7.24 36.18 20000000 12676532 
274.29 11.31 56.53 19983254 0 
275.31 11.32 56.60 3660635 0 
346.31 11.33 56.65 1199210 0 
230.28 11.38 56.88 7978807 0 
   
From Table 4.5, it is clear that the three changes at 16 minutes in the first 
dimension are due to the molecular ions m/z 308, m/z 192 and m/z 302. The m/z 
302.18 is characteristic of 10-Hydroxymorphine, where it is present in the G1527-
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027G sample point but is absent at the G1527-027O sample point. As the G1527-
027G sample point directly follows G1527-027O the lack of this mass in the data 
is possibly due to oxidation or other reactions of compounds within the sample over 
time. 10-Hydroxymorphine is a degradation product of morphine [188] leading to 
the possibility that it further degrades under the right conditions to form a different 
impurity. As the morphine and other unknown compounds are removed through 
crystallisation, new compounds now constitute a significantly higher percentage of 
the remaining liquors and due to this the large change in the presence of 10-
Hydroxymorphine can be more easily observed. This is consistent with unpublished 
data from Sun Pharmaceuticals where under high pH an increase in three as yet 
unknown impurities has been observed [174]. This again highlights how this type 
of comprehensive sample analysis can identify key changes and can enable the 
company to prioritise points of interest for detailed investigation.   
This is supported by the second dimension separation where m/z 302.18 is 
at an adjusted retention time of 0.288 minutes, which is consistent with the PCA 
loadings plot identifying the second biggest change at 16 minutes in the first 
dimension and 0.3 minutes in the second dimension. Also consistent is the intensity 
change, whilst in the first dimension this mass was absent in G1527-027O, the 
second dimension had a relatively small intensity (4697069 counts) indicating that 
the mass is present at a much lower concentration than in G1527-027G (19633025 
counts) again a direct observation of the successful elimination of a range of 
impurities at this point of the morphine processing stream.     
Importantly several other key components have been identified via this 
process which may be targets for further study by Sun Pharmaceuticals when 
defining future issues for customers. The change at 24 minutes is from the 
molecular ions m/z 490, the change at 32 minutes m/z 314, the change at 36 minutes 
m/z 328 and the change at 56 minutes from m/z 274. After discussion with Sun 
Pharmaceutical scientists the molecular ion m/z 314 has been postulated to be 
codeine methyl ether which is commonly observed in these extracts. Codeine 
methyl ether has previously been reported for use to make thebaine with high yields 
(83 %) in comparison to other potential starting products making it an important 
alkaloid with prospective commercial viability [25].  
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Case 2: G1527-027L and G1527-027M 
Case 2 is also from the morphine processing stream however the focus here 
is on the solvent waste procedure. Sample points G1527-027L and G1527-027M 
are both partially spent solvent and it is important to note they come from two 
different Karr reciprocating-plate extraction columns that are used in this stream 
before the next step and are expected to contain similar components. An example 
of a Karr reciprocating column is shown in Figure 4.11 as described by Smith et al. 
[189]. It is a solvent extraction column that utilises plates that move in a 
reciprocating fashion to separate and purify components [190] and as such has a 
wide variety of applications in chemical industries, including pharmaceutical and 
petrochemical [189]. The difference between the two columns is that the first 
column (sample point G1527-027L) has fresh caustic running through it whereas 
the second column (sample point G1527-027M) utilises the partially rich caustic 
from the first column. The sample G1527-027Q is next in line downstream from 
these and is then followed by G1527-027R, which is recycled in the process at 
sample G1527-027D (Figure 4.4).     
 
Figure 4.11: Depiction of a Karr reciprocating plate-extraction column as described by 
Smith et al. [189]. 
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As can be noted from the loadings plot in Figure 4.12, there is only one 
major change between G1527-027L and G1527-027M and approximately five 
minor changes denoted by the circle diameter. The PC1 loadings values were 
investigated to find the coordinate retention times as displayed in Table 4.6. From 
this plot the major chemical changes can be observed and correlated to the mass 
spectral data. 
 
Figure 4.12: PC1 loadings plot for comparison of G1527-027L and G1527-027M. 
 
Table 4.6: PC1 loadings values for G1527-027L and G1527-027M.  
First dimension 
RT 
Second dimension RT PC1 loadings score 
44 2.7 1.000000 
44 1.5 0.119075 
44 1.4 0.102645 
32 2.9 0.064433 
44 1.8 0.020958 
44 1.6 0.016224 
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The main change between the two large scale processing columns was 
interrogated with LC/MS to determine the mass of the compound which was 
determined to correspond to m/z 171.14. When the 2D-HPLC plots were 
consulted, as shown in Figure 4.13 the change between the two samples by eye is 
small highlighting the importance of this type of PCA data handling. This 
protocol has allowed the biggest changes between the samples to be found and 
scales them from 0 to 1, which is an important aspect to be aware of as in the case 
of these two samples the change is small.  
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Figure 4.13: 2D-HPLC contour plots of the samples G1527-027L and G1527-027M. 
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The ion m/z 171.14 has not previously been identified as a key component 
of interest to Sun Pharmaceuticals. Here for the first time the company has the 
capacity to assess compounds based on the PCA data processing which may afford 
a deeper understanding of the components that play key roles in differentiation 
between samples. This highlights the significance of the work developed here as it 
could be applied to monitoring key low concentration components in batch to batch 
processing samples to help inform process owners.  
Case 3: G1528-028C, G1527-028D and G1527-028H  
This case is from the thebaine and oripavine processing stream and is at the 
point where they are separated from each other. Sample point G1527-028C is the 
rich solvent containing both thebaine and oripavine, they are then separated with a 
caustic wash before G1527-028D the thebaine only stream and G1527-028H the 
purely oripavine stream. The 2D-HPLC contour plots for these samples are shown 
below in Figure 4.14.  
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Figure 4.14: 2D-HPLC contour plots for G1527-028C and  G1527-028D. 
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As highlighted by the contour plots (Figure 4.14) there are minimal small 
changes observed between these two samples, however importantly there is one 
large change which is due to the removal of oripavine from the stream. This was 
also confirmed by the mass spectral data that showed the key change was due to 
m/z 298 the molecular ion of oripavine which has been extracted. The second 
largest observable change was m/z 344 which was confirmed with the use of the 
standard to be the molecular ion of laudanine. This again highlights the complexity 
of real world process chemistry samples and that isomers can be challenging to 
monitor. Here we have shown that we can differentiate between key compounds of 
the same mass and as such add to the capacity for Sun Pharmaceuticals to 
interrogate samples more clearly.   
This clear data set could be easily used as a visual inspection tool by the 
process owners to quickly assess the quality of the separation of thebaine and 
oripavine. In this case PCA data analysis would only be required to understand the 
significance of the minor components within this sample. The components of low 
concentration observed here are likely to be compounds that prefer solvent 
conditions in the oripavine stream over the thebaine stream. This will be primarily 
driven by the pH adjustment afforded by the caustic wash step and could be a key 
point in the process where Sun Pharmaceuticals could focus on for efficiency 
improvements. 
The differences between sample points G1527-028C and G1527-028H 
were then investigated to see what followed in the oripavine stream, where the 
biggest change is expected to be the removal of thebaine. The contour plots were 
first compared to identify the obvious changes in the two samples. Figure 4.15 
shows the contour plot for sample point G1527-028H (rich in oripavine), and when 
compared to G1527-028C (Figure 4.14A) the removal of the large peak associated 
with thebaine at 40 minutes (First Dimension) and 2.4 minutes (Second Dimension) 
can be observed.  
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Figure 4.15: Contour plot for G1527-028H. 
 
The PC1 and PC2 loadings plots and scores were then consulted to 
determine other changes that may be significant to the process. It was important for 
the PCA that the samples were of the same concentration to eliminate a big change 
being identified due to differing concentrations. Due to this G1527-028H was 
diluted by a further factor of 10 to bring it into line with G1527-028C and G1527-
028D before PCA was applied. As can be noted in the PC1 loadings plot of G1527-
028C and G1527-028H (Figure 4.16), the biggest change identified is the removal 
of oripavine.  
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Figure 4.16:  PC1 loadings plot for the comparison of G1527-028C and G1527-028H. 
 
Figure 4.17: PC2 loadings plot for the comparison of G1527-028C and G1527-
028H.Showing the comparison between the two samples  
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The location of the major change (removal of thebaine) in Figure 4.16 is at 
40 minutes in first dimension and 2.65 minutes in the second dimension. The next 
biggest change is observed at 48 minutes in the first dimension and 2.75 minutes in 
the second dimension and was identified as the previously mentioned molecular 
ion m/z 171, highlighting the need for further investigation into this molecule that 
is beyond the scope of this project.  
This case highlights the importance of this protocol in processing samples 
of increased complexity. It was clear from the 2D-HPLC contour plots that this data 
was more complex than those previously investigated and it has been shown that 
the key compounds of interest can be identified. Importantly minor constituents 
have been observed to contribute to the loading plots and these compounds can now 
be tabulated into data sets that could be applied for future use by Sun 
Pharmaceuticals. The key use of these data sets will be to have a focus for any 
future queries on these types of samples and gives Sun Pharmaceuticals some 
capacity to pre-empt areas of concern/interest to clients.         
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Conclusions 
Three masses of interest have been explored and traced through the 
processing stream to determine if they originate from the opium poppy itself or as 
a product of the extraction and isolation process. All three masses (unknown 
impurity MW285, Nor-thebaine and O-M-Somniferine) were identified in the first 
sample extracts and as such were deemed to have originated in the opium poppy 
itself before being extracted alongside the target compounds.     
The methods described in Chapter 2 and 3 have successfully been applied 
to determine the differences between points of interest on the manufacturing 
stream. Three points of interest from the opiate processing stream were investigated 
and using a combination of 2D-HPLC, PCA and LC/MS differences could be 
elucidated. The concept was proven to be effective by focusing on a major known 
change, in which PCA identified this as a large area of difference on the two-
dimensional plots and was confirmed with  mass spectrometry taking into account 
the chromatographic variations observed between the two instruments. These 
techniques provide Sun Pharmaceuticals with the means to identify large areas of 
change between stages of the process or batches and to pinpoint the associated 
masses. This is a tool that can be utilised as a quality control method for the 
company or to pinpoint potential impurities.         
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CHAPTER 5: 
IDENTIFICATION AND SELECTIVE DETECTION OF 
SYNTHETIC CANNABINOIDS 
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Chapter overview 
This chapter investigates the isolation of synthetic cannabinoids from herbal 
substrates followed by a systematic study of selective detection methods for these 
compounds. Several herbal blends purchased in Victoria, Australia before the 
recent ban are explored in order to detect and determine the synthetic cannabinoid 
compounds present. Numerous standards were also synthesised at Deakin 
University to fully test the detection methods on a variety of different compounds. 
Chemiluminescence was used to detect these compounds with three different 
reagents, of which two proved successful for the detection of all but two of the 
thirteen synthetic cannabinoids. Limits of detection were calculated with both 
reagents for all standards and an estimated concentration of the cannabinoids on the 
corresponding herbal substrates was determined. A solid phase extraction 
selectivity study was also conducted, with the use of 6 different sorbents in order 
to improve the isolation of the cannabinoid from the chemically complex herbal 
substrates.  
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Introduction 
Synthetic cannabinoids have been abused since the early 2000s, and have 
become of increasing concern to law enforcement agencies and health 
professionals. These drugs have a vast array of side effects and as highlighted in 
Chapter one (Figure 1.3), are responsible for many disastrous effects for users of 
these herbal alternatives [40, 42]. There are a large number of known synthetic 
cannabinoids and new analogues are constantly entering the market [191]. New 
synthetic cannabinoids have been produced by varying the (usually heterocyclic) 
core, bioisosteric replacement and/or changing or adding functional groups, often 
with the intention of creating derivatives that were not prohibited by the law [44, 
192, 193]. 
Currently to determine these compounds the samples are first extracted 
using organic solvents (e.g., methanol, ethanol or acetonitrile) to exploit the non 
polar nature of the synthetic cannabinoid, typically at a ratio of 1 mL of the solvent 
to 10 mg of dried plant material [37, 194]. Generally, the sample extracts are then 
either sonicated or vortexed and centrifuged before filtering with a 0.45 µm filter 
[38, 112, 195]. The sample extracts are then analysed and the compounds detected 
and identified with a variety of different techniques such as GC and LC mass 
spectrometry [54].  
In previous work, mass spectrometry was used to identify the actives 
present in seven of the twelve synthetic cannabinoid samples utilised in this study 
[196]. This technique for the identification of synthetic cannabinoids has been well 
documented in the literature where it is either coupled to liquid chromatography or 
more commonly gas chromatography [54].  
Chemiluminescence is a sensitive and selective mode of detection, easily 
coupled to HPLC, which has been exploited for the determination of numerous 
compounds of forensic importance [55, 79]. Rasanen and co-workers have used 
gas-phase chemiluminescence nitrogen detection for designer drugs including 
some synthetic cannabinoids [197], but to date, liquid-phase chemiluminescence 
has not been reported for the detection of these compounds. 
Electrochemiluminescence (ECL) is a technique that has also not previously been 
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reported for use with synthetic cannabinoids. Herein, the complementary selectivity 
derived from solvent extraction, chromatographic separation and 
chemiluminescence detection for the determination of synthetic cannabinoids in 
complex herbal sample matrices is explored. 
Solid Phase Extraction 
Due to the complexity of the synthetic cannabinoid samples, removing 
unnecessary components from the samples will aid ‘at scene’ detection. A common 
method of sample clean-up, solid phase extraction (SPE) is a selective and rapid 
preparation method used for isolation, concentration, clean up and medium 
exchange [198]. The aim of SPE is to separate the analytes of interest from the other 
components in the sample before chromatography or analytical methods [198], and 
has been used on the synthetic cannabinoid UR-144 for extraction from the herbal 
product. Kavanagh et al. [61] utilised a C-18 SPE cartridge for this which is a 
cartridge that has also been used for synthetic cannabinoids in urine [199, 200]. 
Whilst SPE is not often used to clean up herbal extractions it is commonly 
used for biological samples where it is an important purification and concentration 
step before mass spectrometry analysis [54]. SPE has also been used for large 
variety of cannabinoids in differing biological samples such as urine [201, 202], 
blood [203] and oral fluid [35, 204, 205]. Urine studies have included extracting 
and quantifying the metabolites of the synthetic cannabinoids JWH‐018 and JWH‐
073 with a strong cation exchange SPE cartridge [206].  
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Experimental 
Chemicals, samples and standards 
Twelve commercially available herbal synthetic cannabinoid samples 
(brands: Puff, Red Dot, Bombay Blue - pineapple flavour, Cloud 9, Code Black - 
strawberry flavour, Northern Lights - Special K, Malibu, Atomic Bomb, Stoner, 
Storm, Supanova and Voodoo; Figure 5.1) were obtained in 2013/2014 pre-ban 
from a range of stores in Victoria, Australia. Synthetic cannabinoids were extracted 
by adding 10 mg of the herbal mixture to 1 mL of the extraction solvent and 
sonicated for 10 minutes. The organic solvents used in this study were acetone, 
methanol, ethyl acetate (Chem-Supply, SA, Australia) and acetonitrile (Ajax Fine 
Chemicals, NSW, Australia); all solvents were of analytical grade or higher.  
 
Figure 5.1: Synthetic cannabinoid brands utilised in this study. 
 
Seven synthetic cannabinoid standards (AM-2201, AB-001, 5F-AKB-48, 
5F-AB-001, JWH-018, JWH-073 and 5F-AB-PINACA) were synthesized at 
Deakin University. A further two synthetic cannabinoid standards (PB-22 and 5F-
PB-22) were obtained from the National Measurement Institute (NSW, Australia). 
Stock solutions of these were initially prepared at 1 mM using HPLC grade 
methanol (Merck, Vic, Australia) and diluted as required.  
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High Performance Liquid Chromatography (HPLC) 
An Agilent Technologies 1260 HPLC with an auto injector, solvent degasser, 
quaternary pump, column thermostat (20°C) and a DAD ( = 254 nm) and 
chemiluminescence detector were used. Chemiluminescence reagents were 
pumped to the custom-made detector with a Gilson Minipuls peristaltic pump at 1 
mL min-1 as described by Adcock et al. (Figure 5.2) [207]. Reagent and column 
eluent were merged at a T-piece shortly prior to entering the coiled tubing flow-
cell, as described by Holland et al. [208] (Figure 5.2). An Agilent Eclipse XDB‐
C18 column (4.6 mm × 15 mm, 5 μm particle diameter) was used for all separations. 
The sample (20 µL) was injected onto the column with a flow rate of 1 mL min-1. 
The mobile phase comprised HPLC-grade methanol (Merck) and Milli-Q water 
(Merck Millipore, Victoria, Australia). In method A, the methanol was increased 
from 0% to 100% over 40 minutes, and then held for 20 minutes, with 5 minute re-
equilibration time. In method B, both the methanol and deionised water contained 
0.1% (v/v) formic acid; the methanol component was increased from 10% to 80% 
over 10 minutes, and then to 100% over 10 minutes, with 5 minute re-equilibration 
time. 
 
Figure 5.2: Custom HPLC chemiluminescence detector setup as described by Adcock et 
al. [207]. Key: q = quaternary pump; v = injection valve; c = column; u = UV-visible 
absorbance detector or other non-destructive detector; p=peristaltic pump; d = flow-
through chemiluminescence detector. 
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Chemiluminescence detection 
A 1 mM solution of acidic potassium permanganate (Chem-Supply) was 
prepared in deionised water containing 1% (m/v) sodium polyphosphate (Sigma-
Aldrich), adjusted to pH 2.5 with concentrated sulfuric acid (Merck). 
The stable tris(2,2′ bipyridine)ruthenium(II) perchlorate salt 
([Ru(bipy)3](ClO4)2) was prepared by an aqueous metathesis reaction as described 
by McDermott et al. [209]. Tris(2,2′ bipyridine)ruthenium(II) chloride 
hexahydrate was purchased from Strem Chemicals (CA, USA) and the sodium 
perchlorate was from Sigma-Aldrich. The [Ru(bipy)3](ClO4)2 salt (0.384 g L-1) was 
dissolved in HPLC grade acetonitrile (Ajax) with 0.05 M perchloric acid (Ajax). 
Lead dioxide (Fluka Analytical) was added (2 g L-1) and the reagent was filtered 
in-line. 
Manganese(IV) was prepared according to the method of Brown et al. [86]. 
Manganese dioxide was formed by reducing potassium permanganate (Chem-
Supply) with an excess of sodium formate (Sigma-Aldrich) and collecting the 
precipitate under vacuum on glass filter paper (GF/A, Whatman, England). The 
solid was washed three times with deionised water. The wet manganese dioxide 
(approx. 1.2 g L-1) was placed in 3 M orthophosphoric acid (85% w/w, Chem-
Supply) and sonicated for 30 minutes before heating (80°C) whilst stirring for 
approximately 1 hr. The solution was then cooled on ice and an iodometric titration 
was performed using potassium iodide (Ajax), where the iodine released upon 
reaction with manganese(IV) was titrated against sodium thiosulfate (Sigma-
Aldrich) solution, with a starch (Ajax) indicator determining the end-point. As an 
enhancer 2 M Formaldehyde (37% w/w, Chem-Supply) was used, merging with 
the HPLC eluent after the DAD but before entering the chemiluminescence 
detector. 
Electrospray mass spectrometry 
Pre‐separated cannabinoid fractions were directly injected into an Agilent 
Technologies 6210 LC/MSD ESI-TOF equipped with a 1200 series solvent 
degasser, binary pump (methanol, 1 mL min-1) and 1100 series ALS. Positive ion 
polarity was used under the following conditions: drying gas (N2), flow rate and 
temperature (5 L min-1, 350°C), nebuliser gas (N2) pressure (30 psi), capillary 
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voltage 3.0 kV, vaporiser temperature 350°C, and cone voltage 60 V. MS data 
acquisition and analysis was carried out using Agilent MassHunter Workstation 
Acquisition for TOF/Q-TOF (version B.02.00 (B1128)) and MassHunter 
Qualitative Analysis (version B.03.01). 
Electrochemiluminescence (ECL) and Cyclic Voltammetry (CV) 
Cyclic voltammetry (CV) was carried out with a glassy carbon working 
electrode, silver wire as the reference electrode and platinum wire as the counter 
electrode. Samples were prepared in dry acetonitrile with 0.1 M 
Tetrabutylammonium hexafluorophosphate ([TBA][PF6], Fluka). A scan rate of 0.1 
V s-1 was utilised for all samples, and each was referenced to 1 mM ferrocene.   
Electrochemiluminescence spectra were collected with a photomultiplier 
tube (PMT). As with the CV experiments a glassy carbon working electrode and 
platinum wire counter electrode was utilised. Synthetic cannabinoid standards at 1 
mM were first tested with Tetrabutylammonium hexafluorophosphate as a blank  
before tris(2,2′‐bipyridine)ruthenium(II) hexafluorophosphate (Aldrich) was added 
and the mixture re-tested. Herbal samples were tested as above, where the synthetic 
cannabinoids (20 mg) were extracted with dry acetonitrile (2 mL).    
Solid Phase Extraction (SPE) 
Six solid phase extraction (SPE) cartridges, detailed in Table 5.1 were 
purchased from Agilent Technologies. The SPE vacuum manifold was purchased 
from Phenomenex (Lane Cove, NSW, Australia).  
Table 5.1: Details of the Solid Phase Extraction cartridges utilised. 
Cartridge Sorbent 
Sorbent Size 
(mg/mL) 
Part Number 
Bond Elut-C18 EWP Silica wide pore C18 50 mg, 1 mL 12102136 
Bond Elut-C8 Silica C8 50 mg, 1 mL 12102059 
Bond Elut-SAX Silica strong anion exchange 100 mg, 1 mL 12102017T 
Bond Elut-SCX Silica strong cation exchange 50 mg, 1 mL 12102075 
Bond Elut-Plexa PCX Polymer strong cation exchange 30 mg, 1 mL 12108301 
Bond Elut-SI Natural silica 100 mg, 1 mL 12102010 
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All SPE cartridges were conditioned as described in Table 5.2, with the 
exception of the natural silica cartridge that was only conditioned with the 
extraction solvent. Samples were extracted at 10 mg of herb to 1 mL of solvent 
(vortexed, filtered and analysed on HPLC) before being added to the conditioned 
cartridge. The cartridges were then washed with 5% methanol (100% extraction 
solvent for silica cartridge) before elution with 100% methanol (100% water for 
silica cartridge). The first pass (sample solution), second pass (wash solution) and 
the third pass (elution) were collected for HPLC analysis. 
Table 5.2: Cartridge conditioning and extraction solvents. 
Conditioning (1 mL each) 
Extraction solvent  
(1 mL/10 mg) 
Methanol , water Methanol 
Methanol , water Acetonitrile 
Acetonitrile, water Acetonitrile 
Methanol , water Acetone 
Acetone, water Acetone 
Methanol, water Ethyl acetate 
Ethyl acetate, water Ethyl acetate 
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Results and discussion 
Synthetic cannabinoid extraction 
Eight different solvents (methanol, ethanol, glacial acetic acid, DMSO, 
DMF, acetone, chloroform, ethyl acetate) were trialled for the extraction of 
cannabinoids from the herbal samples, during earlier work [196]. In that study 
methanol, acetone and ethyl acetate were shown to be the preferred solvents. In this 
work acetonitrile was also tested and compared to those three identified best 
extraction solvents. Chromatograms for extracts from the 'Puff" sample, for 
example are shown in Figure 5.3.  
For each solvent extract from this sample, a large peak was observed in the 
chromatogram at 37.7 minutes (identified as synthetic cannabinoid UR-144, as 
discussed in the following section). The minor components were dependent on the 
solvent used for extraction. Methanol is commonly used for the targeted extraction 
of small polar molecules from within plant matrices [210] and it is likely that the 
minor peaks observed before 25 minutes include polyphenolic compounds from the 
herbal substrate. Due to the absorbance of acetone at 254 nm a large solvent front 
was observed in the chromatogram when it was used for extraction. Acetonitrile 
enabled extraction of large amounts of the cannabinoid without many of the 
extraneous peaks seen with most other solvents and is recommended as the ideal 
solvent for a targeted extraction and reduced sample complexity. Due to the 
inhomogeneous nature of the herbal substrates it is difficult to directly compare the 
concentration of synthetic cannabinoid extracted by the different solvents, however 
all solvents have extracted a significant amount of the target compounds and as 
such a clean extraction is the focus.      
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Figure 5.3: Chromatograms (HPLC with UV absorbance detection at 254 nm; 
separation method A) of the herbal product ‘Puff’ following extraction with: (a) 
methanol, (b) acetone, (c) ethyl acetate, and (d) acetonitrile. The synthetic cannabinoid 
(UR-144) peak can be observed at 37.7 minutes. 
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Identification 
Previously, five synthetic cannabinoids were identified in seven brands of 
herbal ‘incense’ with the use of GC/MS and LC/MS as listed in Table 5.3. These 
seven brands were analysed further in this study in addition to five new herbal 
synthetic cannabinoid samples. Fractions of interest from chromatographic 
separations were collected manually and analysed by ESI-MS to identify the 
synthetic cannabinoids. A tentative assignment was made using ESI-MS, by 
comparing the molecular ion peak to a database of known compounds and utilising 
monographs made available online through www.SWGdrug.org [211]. The 
analysis identified a further three synthetic cannabinoid compounds (Table 5.4). 
The brands ‘Atomic Bomb’, ‘Stoner’ and ‘Storm’ contained the same two 
compounds with m/z 359 and m/z 377, which were provisionally assigned as 
cannabinoids PB-22 and 5F-PB-22. ‘Supanova’ also contained the m/z 359 
compound. The assignments were confirmed by matching the HPLC retention 
times with PB-22 and 5F-PB-22 standards. The brand 'Voodoo' also only contained 
one synthetic cannabinoid (m/z 378) however is only tentatively assigned 5F-AEB 
as there is little information currently available for this compound.   
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Table 5.3: Synthetic cannabinoids previously identified in the extracts of herbal samples. 
Structure Common name(s) IUPAC name Brands 
 
AM-2201 1-[(5-fluoropentyl)-1H-indol-3-
yl]-(naphthalen-1-yl)methanone 
Red Dot 
 
UR-144 (1-pentylindol-3-yl)-(2,2,3,3-
tetramethylcyclopropyl)methanone
Cloud 9; Code Black;  
Puff; Special K  
 
XLR-11 (1-(5-fluoropentyl)-1H-indol-3-
yl)(2,2,3,3-
tetramethylcyclopropyl)methanone
Bombay Blue; Cloud 9; 
Special K 
 
A796,260 [1-(2-morpholin-4-ylethyl]-1H-
indol-3-yl]-(2,2,3,3-
tetramethylcyclopropyl)methanone
Code Black 
 
5F-AKB-48; 
5F-APINACA 
N-(adamantan-1-yl)-1-(5-
fluoropentyl)-1H-indazole-3-
carboxamide 
Malibu 
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Table 5.4: Identified synthetic cannabinoids in the extracts of new herbal samples. 
Structure Common name(s) IUPAC name Brands 
 
PB-22; QUPIC 1-pentyl-1H-indole-3-carboxylic 
acid 8-quinolinyl ester 
Atomic Bomb; Stoner; 
Storm; Supanova 
 
5F-PB-22; 
5F-QUPIC 
1-pentyfluoro-1H-indole-3-
carboxylic acid 8-quinolinyl 
ester 
Atomic Bomb; Stoner; 
Storm 
 
5F-AEB;  
5F-EMB-PINACA 
ethyl (1-(5-fluoropentyl)-1H-
indazole-3-carbonyl)-L-valinate 
*Voodoo 
* Tentatively assigned 
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Chemiluminescence detection 
Chemiluminescence detection has previously been utilised for the detection 
of synthetic cannabinoids in the brands Red Dot, Puff, Cloud 9, Bombay Blue, 
Special K, Code Black and Malibu [196]. From this previous study it was found 
that acidic potassium permanganate didn’t emit light with the synthetic 
cannabinoids unlike the natural cannabinoids [88]. However, they were found to 
react with stable [Ru(bipy)3]3+ for four out of the five synthetic cannabinoids. 
Under identical conditions  (extraction with methanol; HPLC separation method 
B), chromatograms were obtained for all nine synthetic cannabinoid standards 
(Table 5.5) and the twelve herbal samples, with UV absorbance detection at 254 
nm, and then chemiluminescence detection using three different reagents: 
permanganate, manganese(IV) and [Ru(bipy)3]3+. The below Table (5.5) includes 
the standards utilised in this study, in addition to the synthetic cannabinoid brands 
in Tables 5.3 and 5.4. Typical chromatograms produced using the four modes of 
detection (using the ‘Atomic Bomb’ sample as an example) are shown in Figure 
5.4.     
  
 126 
 
Table 5.5: Synthetic cannabinoid standards. 
Structure Common name(s) IUPAC name 
 
5F-AB-PINACA N-(1-amino-3-methyl-1-
oxobutan-2-yl)-1-(5-
fluoropentyl)-1H-indazole-3-
carboxamide 
 
 
5F-AKB-48; 
5F-APINACA 
N-(adamantan-1-yl)-1-(5-
fluoropentyl)-1H-indazole-3-
carboxamide 
  
5F-AB001 Adamantan-1-yl[1-(5-
fluoropentyl)-1H-indol-3-
yl]methanone 
  
AB001 1-pentyl-3-(adamant-1-
oyl)indole 
 
AM-2201 1-[(5-fluoropentyl)-1H-indol-3-
yl]-(naphthalen-1-yl)methanone 
 
JWH-018 Naphthalen-1-yl(1-pentyl-1H-
indol-3-yl)methanone 
 
JWH-073 1-Butyl-3-(1-naphthoyl)indole 
 
PB-22;  
QUPIC 
1-pentyl-1H-indole-3-
carboxylic acid 8-quinolinyl 
ester 
 
5F-PB-22; 
5F-QUPIC 
1-pentyfluoro-1H-indole-3-
carboxylic acid 8-quinolinyl 
ester 
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Figure 5.4: Chromatograms for the same herbal blend extract ‘Atomic Bomb’ obtained 
using separation method B with: (a) UV absorbance detection, and (b-d) 
chemiluminescence detection using (b) acidic potassium permanganate, (c) 
manganese(IV), or (d) [Ru(bipy)3]3+. The two major peaks were assigned as synthetic 
cannabinoids 5F-PB-22 and PB-22 (Table 5.3). 
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The acidic potassium permanganate reagent was examined for the 
chemiluminescence detection of synthetic cannabinoids in the herbal samples 
because it was previously used to detect natural cannabinoids in industrial grade 
hemp [88, 212]. Permanganate reacts with a wide variety of organic compounds 
[213], but a much smaller subset elicit the characteristic red emission (max = 689 
nm) at analytically useful intensities from excited manganese(II) [94, 96, 214]. This 
reagent is particularly effective for the chemiluminescence detection of readily 
oxidisable phenols, anilines and related compounds, but many species outside these 
classes have also been found (sometimes unexpectedly) to generate an intense 
emission [94, 96], including several non-phenolic indoles [215, 216]. When 
screening the cannabinoid standards and herbal samples with this reagent (e.g. 
Figure 5.2b), however, no chemiluminescence signal was obtained but they were 
clearly detected by UV absorbance (Figure 5.4a). In contrast to the alkyl phenol 
backbones of the natural cannabinoids [88], the synthetic mimics investigated here 
are indole and indazole derivatives (Table 5.3, 5.4 and 5.5), and a dissimilar 
chemiluminescence response was not surprising. The permanganate reagent did 
detect some other components of extract, which were likely to include polyphenolic 
compounds from the herbal materials and may pose analytical utility for substrate 
characterisation. 
The chemiluminescence of manganese(IV) also emanates from an 
electronically excited manganese(II) species (λmax = 730 nm) [86], but this reagent 
generates light with a much wider range of compounds than permanganate [97]. 
Despite both reagents forming an excited manganese(II) species, the 
manganese(IV) has a higher maximum intensity (730 nm) compared to acidic 
potassium permanganate (689 nm) due to the addition of the sodium polyphosphate 
enhancer [79]. Non-phenolic indoles, such as tryptamine, tryptophan and 
indomethacin, have been reported to elicit light with manganese(IV) [86, 217]. 
Unlike acidic potassium permanganate, the manganese(IV) reagent produced a 
chemiluminescence signal with each of the synthetic cannabinoids identified in the 
herbal samples (e.g. Figure 5.4c), with the exception of 5F-AKB-48 (both as a 
standard and in the ‘Malibu’ sample). The manganese(IV) reagent also produced a 
chemiluminescence signal with each of the synthesized cannabinoid standards with 
the exception of 5F-AB-PINACA and the aforementioned 5F-AKB-48. The 
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reasons for the stark difference in selectivity between the two manganese-based 
chemiluminescence reagents are yet to be fully elucidated, but appear to arise from 
a combination of the lower oxidation state of manganese(IV) than permanganate, 
the heterogeneous nature of reactions with the colloidal manganese(IV) reagent, 
the concentration of acid and the enhancers added to each system [86, 218-221]. 
The absence of chemiluminescence from the combination of 5F-AKB-48 or 5F-
AB-PINACA and manganese(IV) can be ascribed to the significantly higher 
oxidation potential of these indazole-3-carboxamides compared to the other 
synthetic cannabinoids under discussion [222], which are indole-3-carbonyl 
(ketone or ester) compounds. 
The [Ru(bipy)3]3+ reagent is generally an effective chemiluminescence 
reagent for the detection of aliphatic tertiary amines [92] and although a variety of 
other nitrogen containing compounds also produce light with this reagent, the 
emission intensity is often substantially lower for those with fewer N-alkyl 
substituent's, incorporating mesomeric or resonance stabilisation, or with electron 
withdrawing groups in close vicinity to the nitrogen [223]. Nevertheless, some 
aromatic nitrogen-containing heterocyclic compounds that do not contain 
peripheral amines, including indoles such as tryptophan [224] and indomethacin 
[225], have been reported to produce chemiluminescence upon reaction with 
[Ru(bipy)3]3+ at intensities sufficient for analytical applications. An appraisal of the 
herbal samples with the [Ru(bipy)3]3+ reagent (e.g. Figure 5.4d) showed detectable 
responses for all of the synthetic cannabinoids except 5F-AKB-48 (present in the 
‘Malibu’ sample) and 5F-AB-PINACA, similar to the results obtained with the 
manganese(IV) reagent. 
The standard and herbal extraction of 5F-AKB-48 and the standard 5F-AB-
PINACA both failed to give a chemiluminescence reaction with any of the reagents, 
however a quenching was observed with the manganese(IV) reagent (Figure 5.5) 
The other synthetic cannabinoid intensities varied with the different reagents where 
neither [Ru(bipy)3]3+ nor manganese(IV) proved to be superior to the other (Table 
5.6). Normalised chromatograms (Figure 5.6) highlight that the difference in 
intensity is greatly dependant on the analyte, as is which reagent is more effective. 
For example the standard PB-22 elicits a greater signal with [Ru(bipy)3]3+ (Figure 
5.6a) but the standard AB-001 has a greater response with manganese(IV) (Figure 
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5.6b). [Ru(bipy)3]3+ however, doesn't require an enhancer like manganese (IV) and 
as such would be a more applicable and user friendly reagent for an at-scene 
detection test.  
 
Figure 5.5: Chromatogram of the standard 5F-AKB-48 with UV detection (green) and 
Manganese(IV) (brown). 
Table 5.6. Comparison of chromatographic peak areas for cannabinoid 
standards with chemiluminescence detection (green tick > 115, orange tick 0-115, 
red cross < 0). The 115 scale has been established to allow for clear differentiation 
of the components. 
 
Cannabinoid 
Peak area (a. u.) 
[Ru(bipy)3]3+ Mn(IV) 
PB-22     
5F-PB-22     
AM-2201     
5F-AKB-48     
AB-001     
5F-AB-001     
5F-AB-PINACA     
JWH-018     
JWH-073     
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Figure 5.6: Normalised chromatograms of the synthetic cannabinoid standards PB-22 
(Blue) and AB-001 (Red) with [Ru(bipy)3]3+ and Manganese(IV) detection respectively. 
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Mobile phase was also found to have an impact on the signal produced by 
[Ru(bipy)3]3+. These particular analytes emit a larger signal with a methanol mobile 
phase in comparison to an acetonitrile mobile phase (Figure 5.7) The manganese 
reagents also require a methanol mobile phase as acetonitrile quenches the signal 
[94]. 
 
Figure 5.7: [Ru(bipy)3]3+ comparison of acetonitrile and methanol mobile phase for the 
standard 5F-AB-001. 
  
Solutions of the synthetic cannabinoids standards were used to generate 
calibration curves using HPLC with UV absorbance (254 nm) and/or 
chemiluminescence detection, and the resulting figures of merit are shown in Table 
5.7. It is important to note some calibration equations are linear while others are 
quadratic. The intensities for the quadratic equations fell into the non-linear 
chemiluminescence calibration curve range and as such a second order polynomial 
was fitted to accurately find the limits of detection.  Non-linear calibration models 
are often required when an extended calibration range is utilised [226, 227]. 
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Table 5.7: Analytical figures of merit  
Analyte Detection RT (mins) Calibration Equation R2 LOD (M) 
5F-AB-PINACA 254nm 11.90 y = 1.27 × 106x - 11.2 0.9990 9 × 10-6 
5F-AKB48 254nm 16.81 y = 3. × 106x – 84.2 0.9944 9 × 10-4 
5F-AB001 254nm 16.69 y = 9.86 × 105x - 0.8 0.9987 8 × 10-7 
 Mn(IV) 16.67 y = 1.98 × 105x + 29.9 0.9946 8 × 10-5 
 Ru(bipy)23+ 16.82 y = 41,114.78x + 0.1 0.9952 1 × 10-6 
AB001 254nm 18.85 y = 1.44 × 106x – 0.4 0.9995 3 × 10-7 
 Mn(IV) 18.91 y = 5,342.59x + 1.6 0.9857 3 × 10-5 
 Ru(bipy)23+ 19.04 y = 7.23 × 105x + 1.7 0.9921 9 × 10-6 
AM2201 254nm 14.18 y = 9.92 × 106x – 40.5 0.9999 3 × 10-6 
 Mn(IV) 14.36 y = -2.03 × 108x2 + 5.35 × 105x + 42.9 0.9992 1 × 10-5 
 Ru(bipy)23+ 14.36 y = 1.72 × 105x + 18.5 0.9937 5 × 10-5 
JWH-018 254nm 16.23 y = 1.53 × 106x -1.2 0.9991 8 × 10-7 
 Mn(IV) 16.43 y = 130,085.71x + 9.4 0.9979 3 × 10-5 
 Ru(bipy)23+ 16.37 y = -3.86 × 109x2 + 1.47 × 105x + 0.1 1.0000 4 × 10-7 
JWH-073 254nm 15.25 y = 8.77 × 105x - 1.0 0.9971 1 × 10-6 
 Mn(IV) 15.23 y = 51,200.00x + 22.8 0.9953 5 × 10-5 
 Ru(bipy)23+ 15.39 y = -2.44 × 109x2 + 1.10 × 105x + 0.1 1.0000 9 × 10-7 
PB-22 254nm 14.83 y = 8.25 × 106x + 0.6 0.9998 4 × 10-7 
 Mn(IV) 14.97 y = -9.53 × 109x2 + 1.77 × 106x + 3.4 0.9993 6 × 10-6 
 Ru(bipy)23+ 15.06 y = 8.15 × 106x + 2.2 0.9980 1 × 10-6 
5F-PB-22 254nm 13.21 y = 1.08 × 107x + 23.8 0.9953 1 × 10-7 
 Mn(IV) 13.35 y = -8.57 × 109x2 + 1.87 × 106x + 5.7 0.9979 3 × 10-6 
 Ru(bipy)23+ 13.43 y = 7.51 × 106x + 1.9 0.9975 1 × 10-6 
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From these calibrations, the total cannabinoid content extracted with 1 mL 
methanol from 10 mg of herbal product was calculated. Methanol was used as an 
extraction solvent here for consistency with standards and due its use as a mobile 
phase. The synthetic cannabinoid content was found to range from 0.036 mg to 0.77 
mg per 10 mg of product (Table 5.8). It can be noted that there is considerable 
variation in the amount of cannabinoid material on the substrate. Whilst these are 
only representative of a small selection of all brands that were and are available, 
this highlights the dangers associated with the use of these products.    
Table 5.8: Concentration of synthetic cannabinoid on herbal substrates extractions 
Brand Synthetic 
cannabinoid 
Concentration 
(M) 
Concentration 
(mg/mL) 
Red Dot AM-2201 6.9 × 10-4 0.250 
Malibu 5F-AKB-48 2.0 × 10-3 0.770 
Atomic bomb PB-22 1.3 × 10-4 0.047 
 5F-PB-22 9.5 × 10-5 0.036 
Storm PB-22 9.9 × 10-4 0.360 
 5F-PB-22 3.3 × 10-4 0.130 
Stoner PB-22 1.9 × 10-4 0.068 
 5F-PB-22 1.5 × 10-4 0.057 
Supanova PB-22 2.3 × 10-4 0.082 
 
UV adsorption at 254 nm generally offers a more sensitive detection as 
illustrated in Table 5.7. However chemiluminescence detection affords superior 
selectivity for these samples. The limits of detection determined for the two 
chemiluminescence reagents are similar and hence either could be used for the 
analytes, however [Ru(bipy)3]3+ is a more user friendly reagent as it doesn't require 
a formaldehyde enhancer and extra equipment for analysis [86].  
Electrochemiluminescence (ECL) and Cyclic Voltammetry (CV) 
Electrochemiluminescence involves the use of an applied potential to 
induce a light emitting reaction, which also has the possibility to be used in an at-
scene detection device. Due to the lack of light obtained from the synthetic 
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cannabinoid 5F-AKB-48, the electrochemical properties of the analytes in solution 
were investigated using cyclic voltammetry (CV). The oxidation potential can be 
measured using CV, which in turn can help to understand why a compound elicits 
light with chemiluminescence. Cyclic voltammetry was carried out on seven 
compounds, to determine their oxidation potentials. 
 
Figure 5.8: Cyclic voltammagram (representative of the electron transfer in the system) 
for the synthetic cannabinoid standard 5F-AKB-48 with reference to ferrocene. 
  
The synthetic cannabinoids tested included PB-22 and 5F-PB-22, both of 
which produced a significant amount of light when reacted with [Ru(bipy)3]3+ ,AM-
2201 of which produced a smaller amount of light and 5F-AKB-48 which produced 
no light. Also tested was a precursor (Figure 5.9A) and an analogue (Figure 5.9B) 
of 5F-AKB-48, both of which also did not produce light with chemiluminescence 
(Table 5.9).  
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A)     B) 
  
Figure 5.9: Structures of additional compounds tested to understand the 
chemiluminescence results; (a) 5F-AKB 48 Precursor and (b) 5F-AKB 48 analogue. 
 
Tris(2,2′‐bipyridine)ruthenium(II) itself was also tested to find the 
oxidation potential as was codeine, which is known to produce a significant amount 
of light with this co-reactant. Table (5.10) depicts the oxidation potentials with 
reference to ferrocene. 
Table 5.9:  Comparison of chromatographic peaks areas for additional 
cannabinoid standards with chemiluminescence detection. 
Cannabinoid 
Peak area (a.u.) 
[Ru(bipy)3]3+ Mn(IV) 
5F-AKB-48 Precursor 0 0 
5F-AKB-48 Analogue -24 0 
 
Table 5.10: CV oxidation potentials with reference to ferrocene.   
Sample Concentration (M) Oxidation cf FC 
Ru(bpy)32+ 1.0 × 10-3 0.89 
5F-AKB-48 analogue 1.0 × 10-3 1.18 
5F-AKB-48 Precursor 1.0 × 10-3 1.50 
5F-AKB-48 2.5 × 10-4 1.40 
AM-2201 1.0 × 10-3 1.16, 1. 52 
PB-22 1.0 × 10-3 1.08, 1.25 
5F-PB-22 2.5 × 10-4 1.08, 1.24 
Codeine 1.0 × 10-3 0.64, 1.03 
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                Interestingly, the oxidation potentials of the synthetic cannabinoids are 
higher than the oxidation potential of Ru(bipy)32+. It has previously been thought 
that the Ru(bipy)33+ reagent only produces light with compounds with a lower 
oxidation potential to itself (0.89), such as codeine. However the cannabinoids with 
oxidation potentials 1.16 and below produced chemiluminescence and those above 
1.18 produced no emission with tris(2,2′‐bipyridine)ruthenium(II). This is 
important as it sets an oxidation potential limit to these compounds for 
chemiluminescence detection with tris(2,2′‐bipyridine)ruthenium(II). Some of the 
synthetic cannabinoids have two oxidation potentials indicating they are oxidised 
at one potential and then further oxidised at a higher potential. It is of interest that 
the compounds that have two oxidation potentials are those that produce light with 
chemiluminescence.       
Electrochemiluminescence (ECL) was then trialled to determine which 
compounds produced light with Ru(bipy)33+ when a potential was applied. 
Interestingly, cannabinoid 5F-AKB-48, as well as its precursor and analogue 
(which did not exhibit emission with chemiluminescence) were able to produce 
light with ECL, as can be seen in Figure 5.10. In contrast, the standards which could 
be measured with chemiluminescence did not afford signals with ECL. This 
indicates that with the use of both methods combined, all synthetic cannabinoid 
compounds tested in this study could be selectively detected in a portable manner. 
This technique was also carried out for the synthetic cannabinoid herbal 
samples, where extractions were performed with dry acetonitrile to determine if 
this would be a viable at-scene detection method. Six of the synthetic cannabinoid 
brands (Bombay Blue, Cloud 9, Code Black, Puff, Special K and Voodoo) tested 
did not have associated standards and as such whether they would react with ECL 
was unknown. As suspected, five of these synthetic compounds did not produce 
light when subjected to an applied potential. As the standards that produced light 
with chemiluminescence did not react with ECL, it was not surprising that these 
compounds also didn't react with ECL given their affinity for Ru(bipy)23+ 
chemiluminescence. The brand Storm also didn't produce light with ECL, however 
this is consistent with the results obtained from the standards PB-22 and 5F-PB-22. 
The brands Atomic Bomb and Stoner were not tested as they were known to only 
contain PB-22 and 5F-PB-22 in a lesser concentration than Storm.   
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Voodoo (unknown compound) was an exception where light was produced 
with both chemiluminescence and ECL. Supanova also produced light with ECL 
despite being known to contain PB-22, a synthetic cannabinoid whose standard did 
not emit light when subjected to an applied potential. It is proposed that this sample 
contains further unidentified components, as other large peaks were visible on the 
UV HPLC chromatogram. It is possible that these compounds are unknown to date 
as no synthetic cannabinoids could be matched to their respective molecular ions 
in mass spectrometry (m/z 216 amu and m/z 375). Concentration of the compounds 
and NMR analysis would help, however in this instance insufficient quantities for 
NMR analysis of the cannabinoid were able to be collected.    
 
Figure 5.10: Synthetic cannabinoid standard 5F-AKB-48 analogue with ECL detection. 
 
 The brand Malibu contains the synthetic cannabinoid 5F-AKB-48, of 
which a standard had previously been tested (Figure 5.10) and found to produce 
light. The extraction from the herbs produced less light than the standard at 1 mM 
due to a lower unknown concentration of extracted synthetic cannabinoid. This 
however is important as ECL can still be used to detect the extracted synthetic 
cannabinoid and with further optimisation this has the potential to be used in an at-
scene detection test.  
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Solid Phase Extraction 
Six solid phase extraction (SPE) cartridges (C18, C8, SAX, SCX, PCX and 
natural silica) were trialled as a sample clean up method to eliminate components 
co-extracted from the herbs in order to develop a more targeted identification 
protocol. The four organic solvents (acetonitrile, acetone, ethyl acetate and 
methanol) identified as the most efficient at extracting the synthetic cannabinoid 
from the herb were used as the initial extraction solvent. The solvent extractions 
discussed earlier in this chapter indicated that acetonitrile and acetone co-extract 
less components from the herbs but still a significant amount of cannabinoid.  
Samples were extracted with one of the four organic solvents before being 
added to the conditioned cartridge, where it was discovered that the cannabinoid 
was breaking through the sorbent on all cartridges, eluting as the sample was added. 
However other components were generally retained on the sorbent until washing 
with 5% methanol (100% extraction solvent for natural silica cartridge) or elution 
with 100% methanol (100% water for natural silica cartridge).  
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A) 
 
B) 
Figure 5.11: Chromatograms obtained from each stage of SPE extraction (Plexa PCX 
cartridge with methanol conditioning and acetonitrile initial extraction) for the brand 
“Puff” using UV detection A) actual chromatogram (offset) B) zoomed in chromatogram 
(offset). Legend; Initial = before SPE, Sample = first pass, Wash = second pass and 
Elution = third and final pass. 
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As can be seen from Figure 5.11, the characteristic chromatograms 
produced from the extraction of the brand “Puff” have a large peak at 
approximately 17 minutes which is the synthetic cannabinoid UR-144. The 
chromatograms also show a small peak at the beginning which is likely to be a 
solvent front from the extraction solvent. The peak at approximately 13 minutes is 
an impurity as it is also present in blank samples. This and all other peaks are very 
small in comparison to the cannabinoid peaks. Figure 5.11B shows that there are 
still peaks in the sample solution however in comparison to the sample pre-solid 
phase extraction it can be noted that they have been reduced.  
The solution collected from the wash also contains a large amount of 
cannabinoid, which is potentially from the residual sample solution held in the 
sorbent as it can’t be allowed to dry out during the SPE process. It is expected that 
the cannabinoid should be retained on the sorbent however due to the large 
concentration of the cannabinoid, it breaks through the sorbent in the sample. The 
synthetic cannabinoid is still present in the elution solution due to the sorbent 
retaining a certain amount of the compound. Previous testing indicated that at a 
smaller concentration the synthetic cannabinoid is also fully retained until the third 
and final pass, however the other non-polar compounds are also retained, leading 
to the use of these cartridges as a filtration system with a large concentration of 
synthetic cannabinoid [196].  
   The initial extraction of each sample was analysed with HPLC before SPE 
was performed as this provided the opportunity to see how much of the cannabinoid 
was lost during the SPE process.   
Table 5.11: Results of solid phase extraction for the brand Puff. 
Cartridge Conditioning Extraction solvent
No. of 
Peaks 
% 
Retained
Silica Ethyl acetate Ethyl acetate 4 57 
C8 Acetonitrile, water Acetonitrile 3 54 
C18 Acetonitrile, water Acetonitrile 3 58 
C18 Methanol, water Acetonitrile 2 55 
SAX Acetone, water Acetone 5 52 
SCX Acetonitrile, water Acetonitrile 5 63 
PCX Acetonitrile, water Acetonitrile 4 55 
PCX Methanol, water Acetonitrile 4 62 
 142 
 
As illustrated in Table 5.11, between 52% and 63% of the cannabinoid was 
retained in the sample solution. This means that the solid phase extraction process 
loses approximately 33%-50% of the cannabinoid, however due to the sensitivity 
of the detection this is not an issue. The majority of the cannabinoid was retained 
in the sample solution, however the remainder of the cannabinoid was eluted in the 
wash and elution stages. 
The first pass sample which contains the breakthrough of the synthetic 
cannabinoid was analysed using chemiluminescence detection after optimisation of 
the method. Although the UV indicated that a few small peaks remained in the 
extracted sample after solid phase extraction, when analysed with Ru(bipy)33+ the 
only component that produced light was the synthetic cannabinoid. Figure 5.12 
illustrates this, as even with a sample where 5 peaks are present in the UV other 
than the synthetic cannabinoid peak, the only signal produced by reaction with the 
chemiluminescence was the cannabinoid. This illustrates that the methods outlined 
above are selective for the synthetic cannabinoids. 
 
Figure 5.12: Chromatogram of an acetonitrile extraction for the brand “Puff” after SPE 
with a Plexa PCX cartridge with UV (black) and chemiluminescence (red) detection.  
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Depending on the application and the potential at scene sample matrix 
including contamination, different cartridges may best apply and several should be 
considered. The C18 cartridge provides the cleanest extraction however only 
retains a 55% of the synthetic cannabinoid whereas the Plexa PCX cartridge 
produced a larger number of extraneous peaks but retained a larger percentage of 
the compound of interest. However, when using selective detection such as 
chemiluminescence all tested cartridges can be used as only the synthetic 
cannabinoid reacts with the reagent to produce light. For this application the Plexa 
PCX cartridge was identified to be the cartridge of choice as it was able to provide 
the largest cannabinoid sample.    
The work presented in this chapter provides the ground work for the 
construction of an at-scene detection test to elucidate if a synthetic cannabinoid is 
present on an herbal substrate. The ideal extraction solvent, acetonitrile in 
conjunction with a C18 sorbent has been shown to selectively isolate synthetic 
cannabinoids in a concentration large enough for detection. Two detection systems 
have been trialled here and with further optimisation there is potential for both to 
be effective in revealing if these compounds are present. Chemiluminescence and 
ECL have both been investigated for use in microfluidics devices and all synthetic 
cannabinoids tested here have succeeded with at least one of the two methods. 
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Conclusions  
The need for a selective detection method for synthetic cannabinoids has 
been highlighted by the vast quantity of available compounds and blends. Polar 
organic solvents such as methanol, acetone and acetonitrile provided the most 
efficient and selective extraction of the target synthetic cannabinoids from the 
herbal materials, which in the products under investigation here were identified as 
seven known indole and indazole derivatives. Following solvent extraction, the 
synthetic cannabinoids can be determined by chromatographic separation and UV 
absorbance detection.  
Chemiluminescence with the manganese(IV) or [Ru(bipy)3]3+ reagent was 
shown to be a viable alternative for the post-column detection of most synthetic 
cannabinoids, although the limits of detection were generally poorer than those 
using conventional UV absorbance. The inherent advantages of 
chemiluminescence, however, such as superior analytical selectivity and the 
relative simplicity of detector components are attractive for the development of 
rapid separations and/or at-scene devices for preliminary screening applications. 
This preliminary exploration of the chemiluminescence detection of this controlled 
class of compound shows that there is considerable scope for further development 
in this area.  
Solid Phase extraction following a simple solvent extraction with 
acetonitrile and a C18 silica cartridge increases the selectivity the extraction and 
eliminates the need for a separation technique. This allows the synthetic 
cannabinoids to be selectively detected with chemiluminescence without the need 
for separation. The methods developed here provide the background chemistry for 
an at-scene detection device for synthetic cannabinoids on unknown herbal blends.      
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CHAPTER 6: 
TARGETED NMR SPECTROSCOPY FOR SELECTIVE 
DETERMINATION OF SYNTHETIC CANNABINOIDS 
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Chapter overview 
This chapter delves into the use of NMR spectroscopy to directly detect 
synthetic cannabinoids on the chemically complex herbal blends. The main focus 
of this is on the use of solid state NMR, a novel technique not previously used for 
the detection of compounds on already difficult substrates. This technique affords 
no damage to the sample which is of particular importance for forensically 
significant samples. Experiments investigated included fluorine and both spinning 
and static proton NMR. Carbon experiments were also completed with single pulse 
excitation and cross polarisation to proton nuclei.     
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Introduction 
Synthetic additives sprayed onto plants range from crop protectants such as 
herbicides to illicit substances such as synthetic cannabinoids. The emergence of 
synthetic cannabinoids has prompted investigations into techniques to detect these 
man-made chemicals. The current practices for the determination of synthetic 
cannabinoids on herbal substrates involve onerous sample preparation and result in 
the destruction of the samples; for example, a solvent or solid phase extraction prior 
to chromatographic separation (HPLC or GC) coupled with mass spectral detection 
[228-230]. Ideally, multiple techniques could be combined to give an enhanced 
fingerprint. While examples exist where solution-state nuclear magnetic resonance 
(NMR) spectroscopy has been used for the confirmation of chromatographic peaks 
of forensic interest [231, 232] this analysis is performed post-fractionation. Solid-
state NMR is an informative and versatile characterisation technique able to 
provide quantitative structural information from inhomogeneous samples in a non-
destructive manner [233-235]. Nevertheless, due to the very weak nuclear 
polarisation and correspondingly low inherent signal strength, the ability to directly 
detect compounds on surfaces using this method is challenging. The majority of 
solid-state NMR studies of surface chemistry involve high surface area materials 
such as zeolites [236], metal-organic frameworks [130] or nanoparticles [237]. 
Although not often used for surface chemistry it is an important technique for 
biomolecules [132], nanotechnology [132] and pharmaceuticals [238]. Importantly, 
from a forensic perspective where samples are precious, solid-state NMR is a non-
destructive analytical technique that requires little to no sample preparation [239]. 
This is also particularly important for samples that can degrade when extracted with 
solvent. The amount of sample required is generally between 2 mg and 100 mg 
depending on the size of the magic angle spinning (MAS) rotor, and typically drug 
seizure samples are well in excess of this amount [240]. 
The technique is not as widely used as solution state NMR due to its low 
resolution, however this can be improved with techniques including magic angle 
spinning (MAS) and cross polarization (CP) [236]. Magic angle spinning (MAS) is 
an essential technique that allows better resolution of peaks as opposed to static 
analysis. This involves the rotor being spun at a magic angle with respect to the 
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magnetic field, which narrows the normally wide lines thus improving spectral 
resolution [239]. Cross polarisation (CP) is commonly used in solid state NMR to 
improve the signal to noise ratio and obtain a more rapid analysis [241]. Cross 
polarisation is the transfer of more abundant nuclei such as 1H and 19F to polarise 
rare nuclei, including 13C and 15N [242]. Signal enhancement technologies such as 
dynamic nuclear polarisation (DNP) have boosted the sensitivity of solid-state 
NMR and are opening up a new field of NMR surface characterisation [243].   
Previous work utilising solid-state NMR for surface analysis found 
sensitivity to be an issue in the detection of surface-immobilised peptides on gold 
nanoparticles [244]. In this publication Ashbrook et al. highlight the basic 
approaches which can inform on how solids are influenced by anisotropic 
(orientation-dependant) interactions including dipolar couplings and chemical shift 
anisotrophy which is the driver for the broadening of peaks and subsequent loss in 
ability to utlitise the solid state NMR spectra. While magic angle spinning and 
decoupling and cross polarisation techniques are used to improve sensitivity and 
resolution, solid state NMR has not been used in the capacity highlighted in this 
thesis where molecules of interest are interrogated on a solid substrate.  
Significant research was also required in the surface analysis of metal 
organic frameworks to improve sensitivity where techniques such as the use of 
microwaves to induce DNP were required [130]. The techniques outlined here are 
standard solid-state NMR methods and equipment, not requiring modification to 
the probe as was required in the investigation on surface ethoxy species of acidic 
zeolite Y [131]. Early work of solid state NMR has been performed in order to 
highlight key features of a surface modification of substrates including silicon [245] 
where the reactivity of hydroxyl functional groups on silica with 
trimethylchlorosilane (TMCS) was investigated. Interestingly the authors noted 
that the technique was able to differentiate between germinal and vicinal silanols 
enabling a reactivity mechanism to be postulated. A spectroscopic analysis was 
performed however FTIR-PAS and XPS had the capacity to distinguish the features 
afforded by this early solid state NMR. This concept was fully realised by Pallister 
et al. [246] where quantitative surface coverage analysis was performed on thin 
films. This study was able to exploit both 29Si and 13C NMR to generate data on 
group V gallium thin films which are wide band gap materials of great interest to 
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optoelectronics and semiconductor manufacturers. In 2000 Ladizhansky and co-
workers [247] interrogated the water binding efficiency on the surface of CdS 
nanoparticles that had precipitated from an aqueous solution. In this instance 1H 
NMR (MAS) was used to great effect highlighting that three different bindings sites 
of the water lead to three different lines in the NMR spectra. Other surfaces have 
been studied including nanocrystalline materials such as hydroxyapatite where 
Jager et al. [248] were able to fully characterise the material. While solid state NMR 
is a fully established technique for the structural characterisation of material on the 
atomic scale limited work has been performed on molecules on complex substrates 
such as the herbs presented here. Complex backgrounds as demonstrated by these 
herbal blends have not been reported before and as such the discovery of the 
potential applications outlined here are particularly important.  
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Experimental 
Samples 
The samples used were brands of herbal based synthetic cannabinoid 
products purchased pre ban from various adult and herb stores across Victoria, 
Australia. Brands studied were Red Dot, Puff, Bombay Blue, Cloud 9, Special K, 
Code Black, Malibu, Atomic Bomb, Storm, Stoner, Supanova and Voodoo. 
Damiana (turnera diffusa) was purchased from the happy herb shop, Geelong, 
Victoria, Australia. Approximately 100mg of each sample was ground to a fine 
powder using mortar and pestle which was then packed into a 4 mm o.d. MAS 
NMR rotor for analysis.   
Instrumentation and Experiments 
A Bruker Avance III 300 MHz Wide Bore was used for all analyses in 
conjunction with a 4.0 mm MAS HX probe (Preston, Victoria, Australia). All 
experiments were run at 10 kHz MAS spinning rate except for a static 1H 
experiment that was carried out on all samples with 4 scans. A 1H MAS experiment 
was also carried out with 4 scans. 19F was only carried out on 9 selected samples 
with a minimum scan time of 2 hours. 13C CP MAS was carried out at 7.05 T on all 
samples with a minimum of 2000 scans and a recycle delay of 5 seconds. 13C single 
pulse excitation (SPE) was carried out on 3 samples (Damiana, Bombay Blue and 
Cloud 9) at a T1 relaxation time of 10 seconds and on two samples (Damiana and 
Bombay Blue) with a T1 relaxation time of 60 seconds.  
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Results and discussion 
Given that the cannabinoid is sprayed onto the substrate using a volatile 
solvent (typically acetone) it was reasoned that the cannabinoid might be ordered ( 
potentially crystalline) on the surface and as such discernible from the herbal 
substrate. Initial 13C MAS and 1H-13C cross-polarisation (CP) MAS NMR 
experiments carried out on the brand Bombay Blue and Damiana confirmed that 
the synthetic cannabinoids could be identified using this technique as it was evident 
that the peak widths of the synthetic molecule were systematically narrower than 
that of the herbal substrate, indicative of an ordered solid phase (Figure 6.1). This 
feature facilitated ready identification of the signals arising from the synthetic 
molecules. Damiana (turnera diffusa) was used as a reference for all NMR 
experiments as this herb is most commonly used as a substrate for these commercial 
products. This allowed the background spectrum generated from the substrate to be 
subtracted, revealing the detailed synthetic cannabinoid spectrum.    
For example, subtracting the 13C spectrum of the substrate herb from that of 
the Bombay Blue sample clearly revealed the 13C solid-state NMR spectrum for the 
cannabinoid XLR-11 (Table 5.3) and its distinct structural features as shown in 
Figure 6.1. The distinct structural features of XLR-11 correspond to the following; 
the peaks between 0 and 50 ppm correspond to the aliphatic hydrocarbons, the 
peaks between 100 and 150 ppm correspond to the carbons of the aromatic rings, 
and the peak at 195 ppm is attributed to the carbonyl group (C=O ketone). The peak 
at approximately 80 ppm is consistent with a carbon bound to fluorine. 
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Figure 6.1: Normalised 13C CP MAS solid-state NMR spectra of (top to bottom) damiana 
herbs, synthetic cannabinoid brand Bombay Blue (containing Synthetic cannabinoid 
XLR-11) and Bombay Blue with Damiana subtracted. Spectra were obtained with 16,384 
scans.  
 
13C CPMAS experiments were also carried out on the remaining synthetic 
cannabinoid products and the spectra allow different cannabinoids to be clearly 
differentiated as shown in Figure 6.2 and 6.3. The two synthetic cannabinoids can 
be clearly differentiated in Figure 6.2 where the Malibu brand is observed to contain 
the synthetic cannabinoid 5F-AKB-48 while the Code Black product contains UR-
144. The correlation of the NMR peak positions (chemical shifts) to the molecular 
structure allows certain signals to be used as markers of cannabinoid structure class. 
For example, the brand Code Black has a ketone resonance at a chemical shift of 
195 ppm as do all samples containing UR-144, XLR-11 and AM-2201, but is absent 
in samples that do not contain this feature. In contrast, the brand Malibu has an 
amide in its place, resulting in an amide peak at a chemical shift of 160 ppm instead. 
Samples that contain PB-22 and 5F-PB-22 such as the brand Storm have an ester 
peak at approximately 170 ppm. This differentiation in chemical shift due to 
structural differences is illustrated in Figure 6. 3. 
200 150 100 50 0
Chemical shift (ppm)
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Figure 6.2: 13C CPMAS solid-state NMR spectra (normalised and with the Damiana 
herb signals subtracted) from synthetic cannabinoid brands Malibu (5F-AKB-48) (top) 
and Code Black (UR-144) (bottom). 
 
Figure 6.3: 13C CP MAS solid state NMR spectra normalised with the Damiana herb 
subtracted. Synthetic cannabinoid brands from top to bottom are Malibu, Code Black, 
Bombay Blue, Puff, Red Dot, Voodoo, Storm, Cloud 9, Stoner, Special K, Atomic Bomb 
and Supanova.  
200 150 100 50 0
Chemical shift (ppm)
250 200 150 100 50 0 -50
Chemical shift (ppm )
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As seen in Figure 6.1 in the CP MAS spectra, the signals from the substrate 
and the synthetic cannabinoid are comparable in size. Although it indicates the 
relative amount of herb to the active molecule, CP MAS experiments are not 
generally quantitative. Direct 13C solid-state MAS NMR experiments (i.e. without 
cross polarisation to the 1H nuclei) were therefore also carried out, with different 
recycle delays. As illustrated in Figure 6.4 it was found that the 13C T1 relaxation 
times for the herbal substrate were significantly longer than for the synthetic 
coatings. A short recycle delay of 2 seconds therefore effectively suppressed the 
signal from the substrate, while a 60 s recycle delay showed both components. This 
approach, while somewhat more time consuming due to the weak 13C signal and 
long recycle delays required, could potentially allow accurate quantification of the 
components.    
The concentration of the synthetic cannabinoid also has an impact as even 
with 1H-13C cross polarisation, some of the cannabinoid signals known to be present 
in low concentrations in the samples from previous analysis, were too weak to 
resolve in a reasonable timeframe. As shown in Figure 6.3 the brands Special K, 
Atomic Bomb and Supanova lack the peaks corresponding to the synthetic 
cannabinoid compound known to be present with only a spectra of the herbs 
obtained. These samples are known to contain two cannabinoids but in a lower 
concentration than the other samples as was determined in Chapter 5.   
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Figure 6.4: Synthetic cannabinoid brand Bombay Blue with 13C SPE MAS solid state 
NMR. Red spectra is with T1 relaxation time of 2 seconds and Black spectra is with T1 
relaxation time of 60 seconds.   
 
In an effort to circumvent legislation and complicate detection, a large 
number of synthetic cannabinoids were modified to include fluorine substituents 
often as a fluoropentyl chain [44]. With a gyromagnetic ratio almost four times 
larger than 13C and a 100% natural abundance, 19F is both a selective and sensitive 
means of compound characterisation. As such, 19F MAS NMR was performed on 
brands that were suspected to contain a fluorine (e.g. XLR-11, AM-2201, 5F-PB-
22 and 5F-AKB-48). From these samples a clear signal at a chemical shift of 
−218ppm was apparent, characteristic of a primary alkyl fluoride. Synthetic 
cannabinoids identified in the brands Puff and Supanova lack fluorine substituents 
and no 19F NMR signal could be detected as is supported by the lack of a peak at 
−218ppm.  
250 200 150 100 50 0 -50
Chemical shift (ppm)
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Figure 6.5: 19F solid state NMR spectra normalised of synthetic cannabinoid brands 
(from top to bottom) Malibu (5F-AKB-48), Cloud 9 (UR-144 and XLR-11), Bombay Blue 
(XLR-11), Red Dot (AM-2201), Voodoo, Atomic Bomb (5F-PB-22 and PB-22), Code 
Black (UR-144), Puff (UR-144), Supanova (PB-22) and Damiana (plain herb).  
 
As can be seen in Figure 6.5, a further peak at δ50ppm is present in all 
samples including the plain herbal blend, Damiana. This peak was further 
investigated to determine if a fluorine was present in the herbal blend by running 
an experiment on the rotor and cap without a sample. It was found that this fluorine 
peak was also present in the empty rotor spectra and hence is a background signal 
possibly from the rotor cap (Figure 6.6). The rotor is known to be made from 
zirconium dioxide (ZrO2), but the caps for these rotors can be made from a variety 
of different compounds. However, due to the difference in chemical shift it doesn’t 
interfere with the fluorine peak from the synthetic cannabinoids and is not an issue 
when analysing these samples.     
 
200 100 0 -100 -200 -300 -400
Chemical Shift (ppm)
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Figure 6.6: Spectra from the empty rotor, plain herb and a fluorine containing synthetic 
cannabinoid herbal coating.  
 
1H MAS and static 1H NMR (Figure 6.7) were both uninformative on 
whether synthetic cannabinoids were present on the herbal blends. It is generally 
accepted that 1H solid state NMR is low resolution and provides little information 
about the protons. However, information can still be gained from this analysis in 
the form of the mobility of the sample. The mobility of the sample relates to how 
the structure can reorient depending on the domain. For example with polyethylene 
it is in a highly ordered or crystalline domain the polymer chains can only reorient 
very slowly [249]. However if they are in non-crystalline domain the polymer 
chains are more mobile and as such this can give indication of crystallinity of the 
compounds being detected [249]. As the structures and substrates of all he synthetic 
cannabinoids are similar the spectra does not significantly vary (Figure 6.7).    
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Figure 6.7: 1H spin solid state NMR normalised spectra of synthetic cannabinoid brands 
(from top to bottom) Malibu, Supanova, Atomic Bomb, Special K, Stoner, Cloud 9, Storm, 
Voodoo, Red Dot, Puff, Bombay Blue and Code Black.  
 
This thesis highlights that sensitive determination of the synthetic 
cannabinoid is not an issue. In comparison to GC/MS, the technique currently used 
in forensic determination of these compounds, there are some differences and as 
such it would be beneficial to use these methods in conjunction with each other. As 
previously eluded to solid state NMR requires very little sample preparation in 
comparison GC/MS which requires extraction of the compounds into a volatile 
solvent. The sample preparation for GC/MS involves grinding the sample into a 
powder before adding either methanol or ethanol and ultrasonicating for 10 
minutes, centrifuging for a further 5 minutes and then filtering out the herbal blends 
[112, 199]. This takes significantly longer than the sample preparation required for 
solid state NMR where the sample is only ground to a powder before analysis. 
Literature reports the analysis time for GC/MS ranging between 15 minutes and 60 
minutes [111, 135, 199]. Whilst this is an improvement on the 3 hour cross 
polarisation analysis time it is important to note that a comprehensive study on 
improving analysis time was not performed here and could go some way to 
enhancing the techniques highlighted in this chapter.  
80 60 40 20 0 -20 -40 -60 -80
Chemical shift (ppm)
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The use of 13C and 19F solid-state NMR experiments have proven to be a 
powerful, non-destructive approach for the detection of synthetic cannabinoids as 
a component of herbal blends. Using both 13C CP MAS and 19F MAS experiments 
key structural features can be readily differentiated. This has implications and is 
extremely important for forensic analysis of these as the sample isn’t required to be 
destroyed in order to determine if an alterant has been applied. Sample preparation 
is straightforward and these experiments are standard and do not require high 
magnetic fields or fast spinning rates. This approach will only become more 
powerful as sensitivity enhancement techniques such as the recently identified DNP 
become more reliable. Beyond the obvious implications for forensic analysis, this 
approach has the potential to be used in other applications where herbs or plants 
have had compounds added such as herbicides on foreign plant or vegetable 
imports.  
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Conclusions 
Forensically relevant synthetic cannabinoid compounds on the surface of 
herbal substrates have been identified using 13C and 19F solid-state NMR methods. 
Further to this, structural differences in compounds can also be determined. Solid-
state NMR is not typically amenable to the study of molecules on surfaces, however 
the synthetic cannabinoids studied here provide both high sensitivity and 
resolution, indicative of an ordered solid phase. The use of this technique has the 
capacity to deliver a selective detection protocol for synthetic cannabinoids on 
complex forensic samples in a non-destructive manner. This technique also has the 
potential to be used in other applications where a compound has been added to 
herbs or plant material. 
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Future Work 
 
This thesis explores chemistry in both pharmaceutical and forensic science 
areas and as such the application for future research is limitless. The work presented 
here has the potential to be expanded and some ideas have been suggested below. 
The mapping techniques delivered in chapters 2, 3 and 4 illustrate the broad 
applications to the processing streams undertaken by Sun Pharmaceuticals, 
however this technique could be used in other chemical manufacturing companies 
to monitor their processes. The exact limits and requirements for these techniques 
at each stage of the process need to be developed more precisely to target the exact 
information required by the company. This also has the capability to be utilised in 
the identification of new impurities introduced in bespoke batches of crop from a 
range geographic areas and annual growth cycles to identify issues early in the 
process.    
Chapter 4 explored the identification of a few select impurities of interest 
as this is of significant importance to Sun Pharmaceuticals. The future work in 
relation to this portion is to develop techniques to identify the chemical composition 
and the potential impact they have on the final product. In particular the impurities 
such as those at 285 amu for example are of great importance to identify. It has 
been pinpointed from this research where the largest concentration of the 285 amu 
impurity is in the process and as such this sample may be explored in order to isolate 
enough of this compound for NMR analysis. Other impurities of interest are also 
able to be pinpointed as to where they are most concentrated in the stream and as 
such also have a greater potential to be isolated for identification. Newly identified 
impurities have the potential to be isolated in the process and utilised as future 
important medications or as a precursor to make compounds of interest more 
straightforward as was the case with the now indispensable compound, thebaine.   
The main aim of the synthetic cannabinoids study presented in chapter 5 is 
to work towards an at-scene detection test for these herbal substrates. The chemical 
background to allow this device to be made has been achieved however placing it 
into a device is dependent on engineering as there is a fine line as to what can be 
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achieved with both chemistry and engineering. The future aim of the chemistry 
developed here is to fit it into a microfluidic lab on a chip that would allow at scene 
detection of these compounds. In theory these chips would be hand held disposable 
and cheap devices that could connect to a smart phone or similar to give quick and 
reliable results.      
Also in chapter 5, Electrochemiluminescence (ECL) was shown to react 
with some synthetic cannabinoids, however only the surface of this technique has 
been touched. There are a large variety of complexes that can be used in ECL 
including different ruthenium and iridium complexes. Whilst work has previously 
been done on these complexes, their reactions with the synthetic cannabinoids 
could lead to a more targeted approach to these compounds. A fundamental study 
of why some of these cannabinoids elicit light with ECL/chemiluminescence and 
others don't is also of interest.   
In chapter 6, solid state NMR was shown to detect synthetic cannabinoids 
on the surface of herbal blends, which may have implications to detect coatings on 
other plants. To develop this technique further, a larger sample set of synthetic 
cannabinoid standards and different herbal mixtures could be explored to 
potentially build a library of different herbal substrates and synthetic cannabinoid 
spectra. The non-destructive nature this technique offers has implications in 
forensic science and could potentially be used as a screening technique to test if 
synthetic cannabinoids are present and if so the potential class of the compounds. 
To achieve faster and cleaner results the parameters surrounding these could be 
explored and modified to identify the most efficient method.  Future work on with 
this technique could also include exploring areas such as farming where plants that 
chemicals have been applied to could be tested in order to find what remains on the 
surface. 
Importantly continuation of the work in this thesis is currently underway by 
both a PhD and Honours student highlighting the importance of the information 
generated in this thesis affords further scientific endeavours. I wish the students the 
best of luck in their endeavours as I have greatly enjoyed this study program.
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